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Abstract
Background: Bioresorbable scaffolds (BRS) have revolutionized percutaneous
coronary intervention in clinical cardiovascular medicine. As opposed to permanent
alternatives such as metallic stents, BRS have an inherent potential to reduce the
occurrence of untoward events such as vessel re-narrowing or thrombosis by virtue of
undergoing complete and controlled resorption post- implantation. While BRS plat-
forms demonstrate a clear potential to mitigate risk stemming from incomplete vessel
healing, they introduce a new set of considerations to clinical safety and efficacy. Fore-
most among these issues is the fate of and biological response to material by-products
that evolve throughout the scaffold degradation and erosion processes, motivating a
comprehensive assessment of how material design and deployment parameters impact
scaffold performance in the arterial environment.
Dissertation summary: The overall goal of this project is to identify perfor-
mance criteria of BRS for endovascular applications. First, we develop a computa-
tional model to predict scaffold by-product generation and release throughout the
tissue healing process. Parametric studies are used to elucidate the material and
deployment parameters which most significantly modulate by-product fate and thus
patient risk. We next perform an array of in vitro studies to understand how BRS
fracture risk depends on the expansion ratio imparted at implantation. Due to the
inherent potential for fracture during endovascular delivery, BRS over-expansion is a
more serious concern as compared to analogous deployment of metallic stents. Con-
versely, under-expansion increases the risk of thrombosis due to an alteration of in
situ geometry and concomitant disturbance of arterial blood flow. To gain insight
iii
on the effects of scaffold expansion, computational studies are complemented by in
vitro measures of BRS erosion, degradation, radial strength, and drug delivery kinet-
ics under plausible alterations of the degree of expansion. Finally, a dynamic flow
system which mimics arterial blood flows is developed and used to study the effects
of the specific implantation site on BRS performance. Taken together, the studies
encompassed in this dissertation provide an efficient means for iterative evaluation
of candidate scaffolds as well as the basis to optimize material design and delivery
strategies as this technology continues to evolve.
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Chapter 1
INTRODUCTION
1.1 Overview
Ischaemic Artery Disease
Ischaemic heart disease (IHD) is the leading cause of death on a national and global
scale. According to the world health organization, IHD associated mortality in the
world was 12.8% of total deaths (7.25 millions) and in developed countries 15.6%
of total deaths in 2008 (1.42 million) in 2008 [35]. Atherosclerosis, the narrowing
of arterial lumen due to deposition of fatty substances and proliferation of smooth
muscle cell (SMC) in the artery, is the most common cause of IHD. Elevated levels
of cholesterol, hypertension, smoking and other hemodynamic factors damage the in-
nermost layer of an artery, the endothelium, which trigger fatty substance absorption
and provokes SMC proliferation (Figure 1.1). Reduction of arterial blood flow due
to atherosclerosis restricts downstream nutrients transport that may permanently
damage segment of heart muscle and eventually lead to myocardial infarction.
Percutaneous Coronary Intervention
The physical condition of patient, possibility of future complications, the extent of
severity and type of the artery jointly determine the mode of treatment for atheroscle-
rosis. Coronary artery bypass graft (CABG) is preferred for patients having multiple
blockages and diabetes [78], where arteries from a different part of the body are
grafted adjacent to the diseased regions to redirect the blood flow. In less com-
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Figure 1.1 Mechanism of atherosclerosis [34].
plicated conditions with partial occlusion and more stable atherosclerotic plaques,
percutaneous coronary intervention (PCI) is implemented either using percutaneous
transluminal coronary angioplasty (PTCA) or a stent/scaffold.
Introduction of PTCI by Andreas Grüentzig in 1977 started new clinical era of
revascularization [29]. A balloon-tipped catheter is inserted in the body and inflated
in the diseased region to open the artery and restore downstream blood flow. How-
ever, PTCA patency is primarily limited by acute recoiling, constrictive remodeling,
and healing response for neointimal hyperplasia (Table 1.1) [63].
Bare metal stents (BMS) was the next breakthrough technology in interventional
cardiology where metallic scaffold is permanently implanted at the stenotic region.
First human implantations of a self-expanding and balloon-expandable BMS were
in 1986 and 1987, respectively [77, 64]. Although BMS shows few beneficial aspects
over balloon angioplasty in terms of acute occlusion and recoiling, increases in the risk
of thrombosis and restenosis are notable (Table 1.1). Vascular injury during BMS
2
implantation leads to neointimal hyperplasia and requires re-intervention in many
patients [21].
The third generation technology in the PCI field was drug-eluting stet (DES),
where an active therapeutic agent (antiproliferative or immunosuppressant) is either
coated directly on the metal surface or loaded within a polymer coating on the metal
surface. DES effectively reduces the rate of restenosis via inhibition of SMC prolif-
eration and migration. The first approved DES by Federal Drug and Administration
(FDA) was Cypher stent (Johnson and Johnson, USA) containing immunosuppres-
sant sirolimus/rapamycin in 2003. Antiproliferative paclitaxel based DES, Taxus
stent (Boston, USA), was approved by FDA in 2004. Zotarolimu based Endeavor
stent (Medtronic, USA) and everolimus based Xience V stent (Abbott, USA) also
got approval from FDA in 2008. However, the long term outcome is not satisfactory
due to increased risk of late and very late stent thrombosis (Table 1.1) [63, 60, 27].
The future of interventional cardiology is projected to be dominated by fully
bioresorbable scaffolds (BRS), a potentially ideal solution for obstructive coronary
disease. The first BRS was developed and implanted in animals in mid-1980s at Duke
University [80]. Since then, researchers are trying to understand different aspects
associated with BRS that must be overcome prior to clinical implementation.
Bioresorbable Scaffolds
BRS have several inherent potential advantages over all other PCI technologies [60,
27]. Following balloon angioplasty, mechanical support is only temporally required
during the healing period to prevent immediate recoiling - this can be achieved with
sufficiently stiff BRS. The synchrony between scaffold resorption and tissue healing
can potentially address stent thrombosis, vessel vasomotion, late luminal enlarge-
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ment, and late expansive remodeling. BRS can be designed to confer minimal injury
as viscoelastic behavior of most degradable materials favors less-chronic deployment
[12, 74]. Moreover, BRS implantation does not preclude repeated interventions at
the treated site, which is sometimes required and problematic with permanent im-
plants. As with DES, BRS can be used as a reservoir for local drug delivery. Drug
pharmacokinetics can be controlled through tuning materials physical and structural
properties like resorption rate, composition, and morphology.
The first clinical trial of BRS was performed with poly-l-lactide (PLLA) based
Igaki-Tamai stent in 2000, which completely degraded between 18 to 24 months [83].
In months follow up, low restenosis rate and re-intervention rate of 10.5% along with
0.48 mm angiographic loss index were reported. No negative vessel remodeling or
luminal narrowing was also reported after 2 years of implantation (Table 1.2).
Table 1.1 Potential advantages of BRS different PCI techniques [63, 60].
Balloon
Angioplasty
Bare Metal Stent Metallic
Drug-eluting Stent
Bioresorbable
Scaffold
Acute occlusion - + + +
Acute scaffold
thrombosis
NA - +/- +
Subacute scaffold
thrombosis
NA - - +
Acute recoil - + + +
Constrictive
remodeling
- + + +
Neointimal
hyperplasia
- - + +
Expansive
remodeling
+ - - +
Late luminal
enlargement
+ - - +
Late ST/scaffold
thrombosis
NA - - +
Acute occlusion - + + +
+ = Prevented; - = Not prevented; NA = Not applicable.
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The absorbable metallic stent, AMS-1 (Biotronik, Germany) was the first metallic
BRS primarily composed of magnesium (Mg) [18]. After two major revisions, AMS-3
was designed to reduce neointimal hyperplasia through incorporating bioresorbable
matrix for controlled release of antiproliferative drug delivery [60].
The REVA stent (Boston Scientific, USA) is a fabricated from poly(tyrosine car-
bonate). This radiopaque BRS has a noble mechanical locking mechanism, side-and-
lock design, which potentially addresses acute stent recoil [44]. BTI stent (Bioab-
sorbable Therapeutics Inc, Menlo Park, CA) consists of a backbone of polyanhydride
ester based on salicyclic acid and adipic acid anhydride with sirolimus coating. It
takes 9-12 months to fully degrade, whereas complete drug elution takes place within
30 days [39].
Bioresorbable vascular scaffold, BVS, (Abbott, USA) is a PLLA based BRS con-
taining everolimus drug. Two year follow-up data from the ABSORB trial shows no
cardiac death, re-intervention, or stent thrombosis. After 24 months of implantation,
Table 1.2 Currently available BRS in clinical trials [60].
Product Strut
Materi-
als
Coating
Materi-
als
Absorption
Products
Drug
Elution
Duration
Radial
Support
Absorption
Time
Late
Loss @ 6
months
TLR*
Igaki-
Tamai
PLLA Nil LA,CO2,
H2O
Nil 6 months 2 years 0.44 mm 6.7% @ 6
months
AMS-3 Metal-
Mg alloy
Nil NA Nil Weeks >4
months
0.68 mm 9.1% @ 6
months
REVA PDTE
Carbon-
ate
Nil Amino
acid,
Ethanol,
CO2
Yes 3-6
months
2 years 1.81 mm 67% @ 1
year
BTI Polymer
Salicy-
late +
linker
Salicylate
+ dif-
ferent
linker
Salicylate,
CO2,
H2O
Sirolimus
Salicy-
late
3 months 6 months
BVS 1.1 PLLA Poly-
D,L-
lactide
LA,CO2,
H2O
Everolimus 3 months 2 years 0.19 mm 3.6% @ 1
year
*TLR = Target Lesion Revascularization; NA = Not Applicable.
5
the entire scaffold is absorbed in a porcine coronary model, whereas all drugs are
eluted within 4 months. Revised versions of this BRS, BVS 1.1, shows improved
performance with angiographic late loss of 0.19 mm [73].
1.2 Scope
Despite some encouraging outcomes over the first 25 years of BRS clinical deploy-
ment, this technology is still under-utilized due to a myriad of concerns and only
partially understood risk factors. Several distinct challenges need to be overcome for
BRS technology to displace current metallic DES in percutaneous interventions. The
following open questions, hypotheses and specific aims drive this project, which seeks
to ultimately provide a basis for continued advancement of BRS technologies.
Open Questions
1. What are the factors that dictate the fate of material by-products following
BRS implantation?
2. Can released drug and developed material by-product kinetics be independently
tuned in BRS applications?
3. What factors determine the optimal residence time for BRS?
4. Will deployment parameters, such as immediate environment and utilized ex-
pansion, significantly impact BRS performance?
Hypotheses
1. BRS by-product retention and distribution within arterial tissue are dictated
by a complex interplay between polymer degradation, vascular remodeling, and
metabolic clearance.
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2. Several intrinsic material properties that can be controlled during the manu-
facturing process will have differential impact on various metrics of BRS per-
formance.
3. The degree of BRS radial expansion impact the physical properties of the con-
stituent polymeric network and as a result attenuate metrics of scaffold perfor-
mance.
4. Fluid flow enhances the clearance of soluble by-products, and as a result reduces
the autocatalytic component of BRS degradation.
Specific Aims
1. Develop a physics-based computational model that characterizes the bulk degra-
dation and by-product transport from a BRS.
2. Develop a mathematical model to quantify how compositional and structural
parameters affect key metrics of BRS performance.
3. Characterize the effect of radial expansion on scaffold performance and drug
pharmacokinetics using a representative drug-eluting BRS.
4. Quantify time-dependent BRS properties following submersion in static and dy-
namic medium, including alterations in scaffold mechanical properties, retained
mass, and network structure.
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Chapter 2
ASSESSMENT OF MATERIAL BY-PRODUCT
FATE FROM BIORESORBABLE VASCULAR
SCAFFOLDS
1
2.1 Abstract
Fully bioresorbable vascular scaffolds (BVS) are attractive platforms for the treat-
ment of ischemic artery disease owing to their intrinsic ability to uncage the treated
vessel after the initial scaffolding phase, thereby allowing for the physiological con-
ditioning that is essential to cellular function and vessel healing. Although scaffold
erosion confers distinct advantages over permanent endovascular devices, high tran-
sient by-product concentrations within the arterial wall could induce inflammatory
and immune responses. To better understand these risks, we developed an integrated
computational model that characterizes the bulk degradation and by-product fate for
a representative BVS comprised of poly(L-lactide) (PLLA). Parametric studies were
conducted to evaluate the relative impact of PLLA degradation rate, arterial remodel-
ing, and metabolic activity on the local lactic acid (LA) concentration within arterial
tissue. The model predicts that both tissue remodeling and PLLA degradation kinet-
1Shazly T., Kolachalama V. B., Ferdous, J., Oberhauser J. P., Hossainy S., and Edelman E. R.
2012. Annals of Biomedical Engineering. 40(4): 955-965.
Reprinted here with permission of publisher.
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ics jointly modulate LA fate and suggests that a synchrony of these processes could
minimize transient concentrations within local tissue. Furthermore, simulations indi-
cate that LA metabolism is a relatively poor tissue clearance mechanism compared
to convective and diffusive transport processes. Mechanistic understanding of fac-
tors governing by-product fate may provide further insights on BVS outcome and
facilitate development of future generation scaffolds.
2.2 Introduction
Percutaneous coronary intervention (PCI) has transformed clinical cardiovascular
medicine. Polymer-coated, metallic drug-eluting stents (DES) serve as permanent
implants that prevent vessel re-narrowing and control the release of antiproliferative
pharmacological compounds intended to attenuate the neointimal hyperplastic re-
sponse. However, issues related to incomplete vessel healing characterized by poor
re-endothelialization, stent thrombosis, and late clinical fatalities create concerns
about the long-term effects of metallic-based stent platforms [42, 38, 32]. Emerg-
ing technologies attempting to mitigate these risks are now gaining impetus, and
in particular, bioresorbable vascular scaffolds (BVS) comprised of fully resorbable
polymers are being evaluated pre-clinically and clinically across various vascular beds
[12, 40]. While BVS platforms demonstrate a clear potential to mitigate risk stem-
ming from incomplete vessel healing, they introduce a new set of considerations to
clinical safety and efficacy. Foremost among these issues is the fate of and biological
response to material by-products that evolve throughout the scaffold degradation and
resorption processes. Several studies have quantified biodegradable material behavior
in vitro and in vivo [49, 90, 65], but the physical and chemical factors that govern
by-product fate and associated biological response are difficult to quantify in tradi-
tional experimental settings.
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Computational modeling offers an efficient framework to predict and understand
the behavior of resorbable implants. Aliphatic polyesters are a class of polymers for
which the erosion process is typically modeled using a reaction-transport framework,
where degradation is dictated by an autocatalytic hydrolysis mechanism and trans-
port includes diffusion through the polymer matrix [25, 76, 9]. Reaction-transport
models have been applied to a range of aliphatic polyesters, including poly(orthoester),
poly(4-methylcaprolactone), poly(caprolactone), poly(L-lactide) (PLLA), and poly(D,L-
lactide-co-glycolide) [84]. Hybrid models that employ stochastic reaction frameworks
are mathematically complex but offer greater detail of transient polymer composition
[10, 79]. Despite these and other efforts [4, 31, 66], previous models have not been
extended to characterize the various kinetic factors that modulate by-product fate in
the arterial environment. We have applied a reaction-transport framework to study
how the outcome of material by-products released from a tissue-embedded BVS is
governed by the hydrolytic degradation rate of the polymer, vascular remodeling,
and arterial uptake.
We present a three-dimensional computational model of a BVS that is primar-
ily composed of PLLA and fully embedded within an arterial wall. A volume of
tissue surrounding the scaffold that undergoes cellular and extracellular remodeling
post-implantation was represented as a distinct region with time-varying transport
properties throughout the initial phases of erosion. PLLA degradation internal to the
scaffold was modeled as a reaction-diffusion system, and transport of lactic acid (LA)
external to the scaffold was modeled as a reaction-convection-diffusion system cou-
pled with equations governing luminal blood flow. Parametric studies were performed
to quantify how local peak LA concentrations in tissue vary with PLLA degradation
rate, temporal changes in LA transport properties due to tissue remodeling, and LA
metabolism rate. Model predictions indicate that the relative rates of tissue remodel-
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ing and polymer degradation modulate LA transport and suggest that a synchrony of
these processes can minimize transient LA concentrations in tissue. Results further
indicate that LA metabolism does not dramatically affect tissue concentrations and
is an insignificant clearance mechanism relative to convective and diffusive transport.
These observations add to our understanding of the means by which BVS degradation
products are processed physiologically and the factors that may influence biological
response to BVS therapy for coronary artery disease.
2.3 Methods
A three-dimensional computational model exploiting symmetric vessel characteristics
was constructed based on the geometric and compositional characteristics of a repre-
sentative bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, CA).
The BVS implant is manufactured primarily from poly(L-lactide) (PLLA) and conse-
quently yields lactic acid (LA) as a late degradation by-product. A two-dimensional
Figure 2.1 Schematic of the two-dimensional computational domain comprising a
longitudinal scaffold segment (S) fully embedded within the arterial wall (W), a
tissue healing zone (H) that undergoes marked changes in transport properties
post-implantation, and the arterial lumen (L) (not to scale).
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schematic of the computational domain utilized in this study depicts four geometric
sub-domains: a longitudinal scaffold segment fully embedded within the arterial wall
(S), a tissue healing zone (H) with transient transport properties at early implanta-
tion times, the remaining portion of the arterial wall (W), and the arterial lumen (L)
(Figure 2.1). A three-dimensional geometry reflecting these sub-domains was con-
structed using SolidWorks (Dassault Systèmes) [45], where the diameter and length
of the lumen were and respectively, and the thickness of the healing zone and arterial
wall were and respectively (Figure 2.2A)
Blood was considered as an incompressible, Newtonian fluid, and its flow through
the lumen was assumed to be steady, laminar, and fully developed. Luminal flow was
described by the momentum and continuity equations as follows:
ρL (uL · ∇)uL = −∇PL + µL∇2uL (2.1)
∇ · uL = 0, (2.2)
where uL, ρL = 1060 kg m−3, µL = 3.5× 10−3 Pa-s, and PL are respectively blood
velocity, blood density, blood viscosity, and pressure within the luminal region.
Blood flow through both the porous arterial wall and healing zone were modeled
using momentum and continuity equations:
ρW (uW · ∇)uW = −∇PW + ( 1
W
)µW∇2uW − (µW
κW
)uW (2.3)
∇ · uW = 0 (2.4)
ρH (uH · ∇)uH = −∇PH + ( 1
H
)µH∇2uH − (µH
κH
)uH (2.5)
∇ · uH = 0, (2.6)
where uW, ρW = 1050 kg m−3, µW = 7.2× 10−4 Pa-s, PW , κW = 1.43× 10−18 m2, and
W = 0.43 are respectively steady-state velocity, density, viscosity, pressure, Darcy’s
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Figure 2.2 (A) Three-dimensional computational model of a fully-erodible scaffold
residing in the arterial wall. Blood is flowing in the lumen and the porous arterial
wall. Insets show high magnification images of the strut (S), arterial wall (W), and
healing zone (H). (B) Lactic acid concentration is maximal at the scaffold core and
diminishes towards the boundary with the healing zone. (C, D) Lactic acid
released from the scaffold is transported through H and W via diffusion and
convection. Lactic acid concentration is highest near the scaffold surface and
reduces towards the perivascular wall. Hydrolytic degradation rate of 1× 10−7 s−1,
lactic acid healing zone diffusivity change rate of 1× 10−7 s−1, and lactic acid
metabolism rate of 1× 10−6 s−1 were used in depicted simulation results. Color
bars represent lactic acid concentration for each inset.
permeability, and porosity characterizing interstitial blood plasma flow in the arte-
rial wall; uH, ρH = 1025 kg m−3, µH = 7.2× 10−4 Pa-s, PH , κH = 1.43× 10−18 m2,
and H = 0.43 are respectively the steady-state velocity, density, viscosity, pressure,
Darcy’s permeability, and porosity characterizing interstitial blood plasma flow in the
healing zone [82].
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PLLA degradation was described by a reaction-diffusion model that considers
autocatalyzed hydrolytic reactions. A simplified first-order degradation model was
constructed based on the following reactions [22, 94]:
S1
K→ n2S2 K→ n3S3 K→ n4S4 K→ n5S5, (2.7)
where Si, ni, and K are respectively polymer species i(i = 1, 2, 3, 4, 5), the stoichio-
metric coefficient of species i, and the effective PLLA hydrolytic degradation rate that
describes the conversion between molecular species. Initial polymer monodispersity
was assumed in all simulations, implying the presence of a single high molecular weight
(100 kDa) species prior to scaffold degradation. Although complete PLLA degrada-
tion would actually yield numerous distinct oligomers, the degradation process was
modeled as a systematic evolution of four oligomers groups (S1 − S4) and eventually
LA (S5). These five species constituted a reduced representation of transient scaffold
composition throughout the degradation and resorption processes (Table 2.1).
Autocatalysis caused by the formation of acid end-groups through each hydrolysis
reaction was assumed to occur only within the scaffold. Oligomers in excess of the
PLLA solubility limit (S1 − S4) were assumed to be static within the scaffold for all
times, with only diffusion and transient release of LA (S5) into the surrounding tissue
Table 2.1 Range and average molecular weight of different species used to describe
the degradation process of a fully erodible PLLA endovascular scaffold.
Species Concentration Mw range Average Mw
(M) (kDa) (kDa)
S1 C1 80 ≤Mw < 120 100
S2 C2 40 ≤Mw < 80 60
S3 C3 10 ≤Mw < 40 25
S4 C4 0.1 ≤Mw < 10 5
S5 C5 0.1 ≤Mw 0.1
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[92]. Transient reaction-diffusion equations in the scaffold were considered as follows:
∂CSl
∂t
= −KC1 −KaC1
√
C5 (2.8)
∂CS2
∂t
= n2KC1 + n2KaC1
√
C5 −KC2 −KaC2
√
C5 (2.9)
∂CS3
∂t
= n3
n2
KC2 +
n3
n2
KaC2
√
C5 −KC3 −KaC3
√
C5 (2.10)
∂CS4
∂t
= n4
n3
KC3 +
n4
n3
KaC3
√
C5 −KC4 −KaC4
√
C5 (2.11)
∂CS5
∂t
= ∇ · (DSC5∇CS5 ) +
n5
n4
KC4 +
n5
n4
KaC4
√
C5, (2.12)
where C1−C5, DSC5 = 10−15 m2s−1, and Ka = 7.5×10−8
√
molm−3s−1 are respectively
the concentration of chemical species S1 − S5, the LA diffusion coefficient within the
scaffold, and the autocatalytic degradation rate constant [31].
The metabolism of LA in both the healing zone and the arterial wall was modeled
as a first-order reaction [43]. LA concentration inside the healing zone was modeled
as transient reaction-diffusion-convection process:
∂CH5
∂t
+ uH · ∇CH5 = ∇ · (DHC5∇CH5 )−Km,HCH5 , (2.13)
where DSC5 and Km,H are respectively LA diffusion coefficient and metabolism rate
within the healing zone [56]. DSC5 was modeled as an exponentially decaying transport
property with an initial maximum value equal to the LA diffusion coefficient in the
lumen (DLC5 = 10−8 m2s−1) and a minimum value that is equal to the LA diffusion
coefficient in the arterial wall (DWC5 = 10−12 m2s−1). The transient value of DSC5 was
modeled as follows:
DHC5 −DWC5 = (DLC5 −DWC5)e−αt, (2.14)
where α is the exponential constant that describes the transformation from blood-
like to arterial-wall like behavior. LA concentration within the arterial wall was also
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modeled as a transient reaction-diffusion-convection process as follows:
∂CW5
∂t
+ uW · ∇CW5 = ∇ · (DWC5∇CW5 )−Km,WCW5 , (2.15)
where Km,W is LA metabolism rate in the arterial wall. LA transport within the
lumen was modeled as transient diffusion-convection process as follows:
∂CL5
∂t
+ uL · ∇CL5 = ∇ · (DLC5∇CL5 ), (2.16)
A fully developed, parabolic velocity profile with a mean velocity of 0.265 m s−1 was
assumed at the luminal inlet [45]. A transmural velocity boundary condition was im-
posed in the normal direction of the mural interface on the basis of Kedem-Katchalsky
equation [41], whereas a constant pressure boundary condition was imposed on the
perivascular wall [81]. Symmetry boundary conditions were assigned both at the ar-
terial wall inlet and outlet, and along the vessel center-line.
For species evolution and transport, S1 with unit concentration was the initially im-
posed within the scaffold sub-domain. Flux continuity of the mobile species S5 was
maintained at the scaffold surface, healing zone-arterial wall interface, and the mu-
ral interface, while a convective flux boundary condition was also imposed at the
perivascular wall. A zero-concentration condition was assumed at the lumen inlet,
as upstream species transport is largely prevented by luminal flow [7, 15]. Con-
versely, downstream species transport is flow-assisted and assumed to be a convection-
dominated process, motivating the use of a convective flux boundary condition at the
lumen outlet [95].
The computational domain was meshed using 102,845 tetrahedral elements, with a
relative tolerance of 10−5 required for solution convergence. An adaptive meshing
procedure was used to create a continuous mesh with maximum density at the scaf-
fold surface and minimum density along the center-line of the lumen, facilitating high
fidelity results in the tissue regions of interest. The finite-element framework (COM-
SOL MultiphysicsTM) yielded a mesh-independent solution that was defined as a less
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than 0.1% relative change in C1 within the scaffold at 24 months following successive
adaptive refinements.
2.4 Results
Our computational model provided converged solutions for the spatial and tempo-
ral distribution of BVS by-products over a wide range of kinetic parameters char-
acterizing PLLA degradation, arterial remodeling, lactic acid (LA) transport, and
metabolism. The spatial distribution of LA within the scaffold was maximal at the
core and decreased towards the boundary with the healing zone for all times, confirm-
ing diffusion-mediated LA transport within the scaffold sub-domain (Figure 2.2B).
However, a substantial amount of LA was transported by transmural convection both
in the healing zone and the arterial wall, evidenced by a greater increase in LA
concentration in the radial as opposed to axial direction within both sub-domains
(Figures 2.2C & D). These trends are a consequence of the simulated average trans-
mural blood velocity (1.64× 10−8 m s−1), which is consistent with the previously
reported experimental results attained within rabbit aortic walls (1.78× 10−8 m s−1)
[54]. Moreover, the LA concentration was evidently higher in the distal compared
to proximal region of both the scaffold and healing zone, indicating that blood flow
affects transport in these sub-domains.
The simulated autocatalytic degradation process resulted in a nonlinear decrease
of the number-averaged molecular weight (Mn) of the insoluble scaffold species post-
implantation (Figure 2.3A). For a given set of parameters, our model predictions
correlate well (R = 0.99, p <0.05) to in vivo measurements of BVS scaffold degrada-
tion [59],providing support for the employed degradation model and analyzed range of
degradation rates. When the PLLA hydrolytic degradation rate (K) was 7.5× 10−8
s−1, the scaffold underwent a rapid reduction of Mn in first twelve months, followed
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Figure 2.3 (A) Simulated number averaged molecular weight change of insoluble
scaffold species (smooth line) as a function of implantation time agree with
previously reported experimental measurements of BVS [59].Insets depict the
relative concentration of the insoluble oligomer species (black bars) and soluble
species (gray bars) within the scaffold domain throughout the degradation process.
(B) The number averaged molecular weight of the scaffold as a function of time for
various hydrolytic degradation rates. Increased hydrolytic degradation rate (K)
leads to a markedly faster reduction in scaffold number-averaged molecular weight.
(C) Lactic acid concentration within the healing zone and arterial wall over five
years post-implantation for various hydrolytic degradation rates. At all times, the
lactic acid concentration is approximately an order of magnitude greater in the
healing zone compared to the arterial wall. A hydrolytic degradation rate of
7.5× 10−8 s−1 was used for (A). A lactic acid healing zone diffusivity change rate
of 1× 10−7 s−1 and lactic acid metabolism rate of 1× 10−6 s−1 were used in all
illustrated simulation results (A-C).
by period of gradual decline to approximately 3% of the initial value after two years.
Transient scaffold molecular distributions (insets in Figure 2.3A) demonstrate that
defined chemical species groups are present in various concentrations through the
degradation process, with a relatively high concentration of LA within the scaffold
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at early times (<12 months post implantation). Early accumulation of LA within
the scaffold implies that the generation rate exceeds the diffusion-mediated transport
rate, a phenomena that is in agreement with previously reported computational re-
sults [67].
An order of magnitude variation in K dramatically affects scaffold Mn over a
two-year period (Figure 2.3B). Mn is reduced by over 40% within one month under
the fastest K (7.5× 10−8 s−1), while an order of magnitude decrease in K results in
less than 1%Mn reduction at the same time point. The significant model response to
variation in K is an expected characteristic of autocatalytic polymers such as PLLA,
where trace levels of LA within the material can substantially accelerate degradation.
The transient LA concentration within the scaffold is consistently orders of mag-
nitude greater than that in the lumen or surrounding arterial wall, suggesting that
the arterial environment behaves as a sink for evolved by-products. The healing zone
is a predefined region of arterial tissue (10% of arterial wall thickness) surrounding
the scaffold that is postulated to undergo changes in transport properties as a con-
sequence of tissue remodeling. As a consequence of proximity to the scaffold, LA
concentrations are consistently higher in the healing zone than in the arterial wall
(Figure 2.3C), implying that local tissue is at a greatest risk of by-product accu-
mulation despite initially accelerated transport associated with incomplete healing.
Transient LA concentrations within the healing zone and the arterial wall follow
similar trends for a prescribed hydrolytic degradation rate (K). However, a strong
dependence of the time course and nature of these trends on K is observed. Under
the fastest K (5× 10−7 s−1), LA concentration sharply increases over the first month,
but is essentially cleared by one year. For intermediate K , there is a moderately
sharp increase in LA concentration over the first ten months followed by a period
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Figure 2.4 (A-B) Hydrolytic degradation rate (K) modulated both peak lactic
acid concentration within the healing zone (Cmax) and the time after implantation
(tmax) at which that concentration occurred. Dependence of Cmax on K follows
U-shaped kinetics, whereas tmax monotonically decreases with K. (C-D) Lactic
acid concentration within the healing zone and arterial wall over five years
post-implantation for various hydrolytic degradation rates. At all times, the lactic
acid concentration is approximately an order of magnitude greater in the healing
zone compared to the arterial wall.
of sustained concentration that persists until approximately 29 months. When K is
lowest (5× 10−8 s−1), a gradual increase of LA concentration occurs over a period of
32 months followed by a protracted decline thereafter.
The peak concentration of LA within the healing zone (Cmax) varied nonlinearly
with K (Figure 2.4A). Trends indicate that Cmax initially has a strong negative de-
pendence on K until a critical limit is surpassed. At K exceeding 1.4× 10−7 s−1,
faster degradation results in slightly greater LA accumulation within local tissue.
The time point at which Cmax occurs (tmax) is monotonically reduced with faster
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Figure 2.5 The ratio of the diffusivity change rate within the healing zone (α) to
the hydrolytic degradation rate of the scaffold (K) was varied between 0.2 and 2 by
altering either rate constant in isolation. (A) The peak lactic acid concentration
within the healing zone (Cmax) generally had a positive dependence on αK regardless
of which rate was varied. (B) The time at which Cmax occurs (tmax) showed a near
binary dependence on α
K
. When α
K
<1, tmax was less than 12 months for all tested
cases; when α
K
>1, tmax was comparatively longer (21 - 35 months).
degradation, and abruptly drops from over two years to less than six months post-
implantation when K approaches the critical limit of 1.4× 10−7 s−1 (Figure 2.4B).
The temporal change in LA diffusivity within the healing zone reflects the transition
from lumen-like to arterial wall-like transport properties as local tissue is remod-
eled. An increase in the exponential rate constant governing diffusivity (α) leads to a
higher Cmax, implying that transient transport properties adjacent to a scaffold can
influence LA accumulation (Figure 2.4C). The values for tmax are nearly constant for
α <5.25× 10−8 s−1 , suggesting that clearance within this regime is not limited by
transport through the healing zone (Figure 2.4D). However, a more complex depen-
dence is observed when α ≥ 7.5× 10−8 s−1, as peak LA levels are not only orders of
magnitude higher as compared to lower rates, but also occur at substantially later
times post-implantation.
The relative rates of transport property change within the healing zone and PLLA
hydrolytic degradation ( α
K
) show bi-modal governance of Cmax (Figure 2.5A). When
α
K
<1, the resultant Cmax is always less than the value observed when αK = 1. Con-
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Figure 2.6 Metabolism of lactic acid is a secondary clearance mechanism from
tissue as compared to convective/diffusive transport. (A-B) The peak lactic acid
concentration within the healing zone (Cmax) and the time at which Cmax occurs
(tmax) were largely independent of metabolism rate (Km), with an effect observed
only at the maximal simulated rate (Km) = 1× 10−3 s−1.
versely, when α
K
>1, Cmax is comparatively elevated. These trends suggest that
LA is most effectively cleared from local tissue when the rate of scaffold degrada-
tion is greater than the rate of conversion from a lumen-like to an arterial wall-like
domain. The operative α
K
also modulates tmax, although in a less uniform manner
(Figure 2.5B). In general, α
K
<1 results in the peak concentrations occurring at earlier
times post-implantation, while α
K
>1 leads to relatively greater tmax.
In all simulations, LA metabolism rates within the healing zone (Km,H) and ar-
terial wall (Km,W ) were set to equal values ( Km,W = Km,H = Km). Two order of
magnitude variations in Km 1× 10−7 s−1 - 1× 10−5 s−1 had an insignificant effect
on both the resultant Cmax and tmax (Figure 2.6A & B). Only an extreme metabolic
rate of 1× 10−3 s−1 influenced transient LA levels in local tissue, with approximately
a 70% reduction in Cmax compared to lower rates.
2.5 Discussion
The ultimate fate of implant-derived chemical species is subject to a complex array
of factors that often preclude delineation through traditional experimentation. Even
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when carefully designed bench-top experiments provide characterizations of material
degradation and erosion, results do not always reflect in vivo performance. Predic-
tion of implant behavior and degraded species fate in vivo is confounded by variations
in governing processes such as species generation/release rates, diffusive/convective
transport, and metabolism, all of which are subject to change based on precise im-
plantation site, implant composition and properties, and patient status. While fully
bioresorbable vascular scaffolds (BVS) have the potential to improve upon current
treatment options for ischemic artery disease, we must understand the numerous
factors that will dictate device safety and efficacy. Complete scaffold erosion could
potentially mitigate long-term risks that limit permanent alternatives, but also in-
troduces new concerns with injurious by-product accumulation in local arterial tissue.
It is critical to account for the transient levels of LA that accumulate in local tis-
sue throughout the implant lifetime to predict the safety of BVS composed of PLLA.
Convective and diffusive transport coupled with metabolic elimination governs nat-
urally fluctuating LA tissue levels in normal physiologic scenarios. While the same
clearance mechanisms would be operative following scaffold implantation, high tran-
sient LA concentrations could arise in local tissue during the erosion process and
create an acidic environment [90]. BVS evaluation, both in terms of functional per-
formance and safety, requires extensive in vivo studies that measure LA generation,
release, and concentration in tissue over the implant lifetime - these experiments are
conducted at high cost and on the timescale of years. Computational modeling offers
an efficient and complementary framework for critical implant assessment and facili-
tates both understanding and prediction of BVS behavior.
In an intriguing fashion, our results predict that the kinetic rates of PLLA hydrol-
ysis (K) and the local change in arterial diffusivity associated with tissue remodeling
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(α) dominate over metabolism (Km) in determining the peak local tissue LA concen-
trations (Cmax). Degradation kinetics modulated Cmax in a complex fashion, with
a trend inflection observed at an intermediate rate within the analyzed parametric
space (Figure 2.4A). The trend results from an interplay between polymer degrada-
tion and arterial healing rates, which is further revealed upon direct analyses of the
dimensionless constant α
K
(Figure 2.5A). LA clearance from local tissue is favored at
low α
K
, where degradation dominates and is far faster than the reduction in transport
associated with healing. The rate of transformation of local tissue from a temporary
clot immediately following implantation (lumen-like) to a stable cellularized substrate
(arterial wall-like) therefore cannot be overlooked when changes in the material struc-
ture and arterial transport properties are on similar timescales. Synchrony between
the degradation and healing processes emerges as a design guideline that can be ap-
plied to BVS, but obviously must be balanced against the need for physical persistence
of the scaffold at the implantation site in order to achieve the therapeutic effect [1, 11].
Our simulations predict that extreme variations in LA metabolism will have a
negligible effect on local tissue concentrations, suggesting that convective and diffu-
sive transport are the primary clearance mechanisms within the arterial environment
(Figure 2.6A. Because scaffold lifetime is presumably independent of LA metabolism
within the tissue, our results imply that patient-specific variations in metabolic ac-
tivity can largely be ignored in designing BVS prototypes for clinical use. Conversely,
the change in LA transport that accompanies tissue transformation is a strong de-
terminant of scaffold safety that may implicate more application-specific variation
driven by deployment protocols and operator techniques.
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2.6 Study Limitations and Future Works
As with most computational studies, results and drawn inferences become all the
more valuable when coupled with experimental and/or clinical data. Previous stud-
ies provided qualitative assessment of the transient tissue response following BVS
implantation in the pig coronary artery [59]. Based on these studies, we were able to
assume reasonable spatial dimensions for the simulated healing zone and confidently
treat this region as being geometrically stable throughout the simulation time. How-
ever, there is no reported study of chemical species transport properties within the
arterial wall and over time. In our model, we assumed that healing zone transport
properties would transition from blood-like to arterial-wall like in a manner that is
independent of local physiological factors. This not necessarily the case in vivo -
local LA concentration could potentially impact tissue remodeling and thus transient
transport properties. In lieu of definitive experimental data, our approach was to con-
duct parametric analyses to predict how the kinetics of local tissue transformation
will modulate LA transport and accumulation. Due to the multitude of simulated
physicochemical processes, technical challenges in related experiments, and long sim-
ulated time periods (∼ 5 years), some model assumptions related to the healing zone
preclude experimental validation and should be carefully considered when interpret-
ing computational results.
While important in modeling flow-mediated transport in the arterial lumen, pre-
vious studies suggest that blood pulsatility minimally influences the chemical species
transport within the arterial wall [95, 45]. Histology of the main coronary artery of
pigs following implantation of BVS indicates that scaffolds are fully-covered by a fi-
bromuscular neointima after only 28 days [59]. As this time period represents just an
early stage of the developed computational model (60 months), we treated the scaf-
fold as a fully embedded implant through the entire simulation time and discarded
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the pulsatile nature of luminal flow. Nevertheless, our developed framework paves
way for future studies that account for various levels of scaffold embedding and/or
blood pulsatility.
Although able to match experimental data for a given set of parameters (Fig-
ure 2.3A), our PLLA degradation model featured a limited number of oligomer/monomer
species generated through abbreviated degradation steps governed by a single rate
constant. Scaffold degradation could be more accurately modeled with either (i) a
probabilistic modifier of the degradation rate constant to describe chain scission from
a longer chain into multiple smaller chains or (ii) a stochastic model governed by the
intrinsic degradation rate constant that allows for generation of all possible oligomers
throughout the degradation process. Moreover, we assumed that the scaffold was ini-
tially a monodisperse polymer matrix with a normalized concentration of the single
species. In the tissue domains, lactic acid metabolism was modeled as a single-step
process governed by a single rate Km, even though the actual metabolic pathway is
considerably more complex. The assumptions driving the employed degradation and
metabolism models enable management of computational cost and facilitate para-
metric analyses of multiple key processes.
Future work should include more realistic models of degradation and increas-
ingly be based on system-specific experimental data. Because of our model assump-
tions, the reported by-product concentrations cannot be directly used to predict clin-
ical safety, but instead enable elucidation of deterministic processes and relation-
ships among various kinetic parameters. While limitations and assumptions must
be taken into account, computational modeling provides a cost-effective approach to
gain new insight on the interplay between tissue remodeling, polymer degradation,
and metabolic clearance in determining by-product retention and distribution within
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arterial tissue.
2.7 Conclusion
Our study suggests that tissue remodeling and polymer degradation kinetics mod-
ulate lactic acid (LA) accumulation within adjacent arterial tissue in the case of a
tissue-embedded, fully bioresorbable vascular scaffold (BVS) comprised of PLLA. On
the other hand, peak LA concentrations were insensitive to large variation in the
tissue metabolic rate, suggesting that metabolism is a secondary by-product clear-
ance mechanism compared to diffusive and convective transport. Synchrony between
rates of remodeling and degradation is predicted to minimize peak LA levels in local
tissue over the scaffold lifetime. As BVS are increasingly considered for the treat-
ment of coronary artery disease, insights on the production and tissue retention of
degradation by-products can help predict clinical performance and provide a basis
for iterative device design.
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Chapter 3
IMPACT OF POLYMER STRUCTURE AND
COMPOSITION ON FULLY-RESORBABLE
ENDOVASCULAR SCAFFOLD PERFORMANCE
1
3.1 Abstract
Fully-erodible endovascular scaffolds are increasingly considered for the treatment of
obstructive arterial disease owing to their potential to mitigate long-term risks asso-
ciated with permanent alternatives. While complete scaffold erosion facilitates vessel
healing, generation and release of material degradation by-products from candidate
materials such as poly-L-lactide (PLLA) may elicit local inflammatory responses that
limit implant efficacy. We developed a computational framework to quantify how the
compositional and structural parameters of PLLA-based fully-erodible endovascular
scaffolds affect degradation kinetics, erosion kinetics, and the transient accumula-
tion of material by-products within the arterial wall. Parametric studies reveal that
while some material properties have similar effects on these critical processes, others
induce qualitatively opposing responses. For example, scaffold degradation is only
mildly responsive to changes in either PLLA polydispersity or the initial degree of
crystallinity, while erosion kinetics are comparatively sensitive to crystallinity. More-
1Ferdous, J., Kolachalama V. B., and Shazly T. 2013. Acta Biomaterialia. 9(4): 6052-6061.
Reprinted here with permission of publisher.
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over, lactide doping can effectively tune both scaffold degradation and erosion, but a
concomitant increase in local by-product accumulation raises concerns about implant
safety. Optimized erodible endovascular scaffolds must precisely balance therapeutic
function and biological response over the implant lifetime, where compositional and
structural parameters will have differential effects on implant performance.
3.2 Introduction
Poly-L-lactide (PLLA) is a bioresorbable polymer considered for multiple clinical ap-
plications due to generally acceptable biocompatibility and tunable physicochemical
properties [80, 5]. PLLA is currently used in the fabrication of resorbable sutures,
wound healing scaffolds, orthopedic fixation devices, and controlled drug/gene deliv-
ery systems [47, 55, 57]. Resorbable endovascular scaffolds composed primarily of
PLLA have been recently proposed as an alternative to permanent metallic devices
[58]. Like traditional stents, resorbable scaffolds can provide sufficient structural sup-
port to prevent acute vessel re-narrowing and serve as a platform for the controlled
release of anti-proliferative or anti-inflammatory drugs. Additionally, resorbable scaf-
folds have the inherent potential to reduce the occurrence of untoward events such as
vessel re-narrowing or thrombosis by virtue of undergoing complete resorption over a
period of two to three years following implantation [59, 58].
Following deployment, endovascular implants are gradually embedded within tis-
sue due to fiber capsule formation and vessel remodeling over the course of approx-
imately four weeks [59]. In the case of fully-erodible PLLA scaffolds that degrade
in vivo over much longer periods, a significant portion of the erosion process will
occur while the implant is in a tissue-embedded state. Embedding will promote local
accumulation of implant-derived soluble by-products, thereby increasing the risk of
inflammatory or immune responses. Risks associated with by-product accumulation
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can detract from the benefits of complete resorption for vascular repair, and motivate
comprehensive assessment of how material design parameters impact polymer degra-
dation and erosion in the arterial environment.
PLLA degrades via an autocatalytic hydrolysis reaction, where an irreversible es-
ter bond scission process creates oligomers and ultimately lactic acid (LA) [25, 9].
Though LA and the readily deprotonated anion L-lactate are common by-products of
the Krebs cycle, excessive concentrations in arterial tissue could alter the local pH and
induce toxicity. Bulk erosion of PLLA scaffolds occurs via diffusion of soluble degra-
dation by-products out of the material network and into the surrounding medium,
resulting in a near homogenous mass loss [76, 71]. A complex combination of factors
governing scaffold degradation, generated by-product transport, and metabolism will
determine the transient LA concentrations in arterial tissue. Previous studies suggest
that scaffold-derived by-product clearance from local arterial tissue is dominated by
transport as opposed to metabolic processes, and that environmental factors such as
the properties of arterial wall and the extent of tissue-embedding significantly impact
the peak LA concentration over the implant lifetime [75]. While environmental prop-
erties and tissue-embedding kinetics vary among individuals, several intrinsic PLLA
properties can be altered in the scaffold manufacturing process and tuned to control
degradation and erosion.
Although several studies characterize the generation, release, and transport of
PLLA degradation by-products in various environments [94, 85, 90], the physical
and chemical factors that influence transient LA concentrations in arterial tissue are
difficult to independently assess with conventional experimental techniques. Degra-
dation and erosion processes are not only affected by initial scaffold characteristics,
including molecular weight, polydispersity, crystallinity, presence of plasticizers, ad-
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ditives, and size, but also by the operating temperature, pH, blood flow rate, and
enzymatic activity [2]. As compared to bench-top or in vivo studies, computational
models can readily provide insight into how these factors independently or collec-
tively impact scaffold performance in situ and insomuch provide design guidelines for
scaffold development. To the best of our knowledge, no computational model has
been reported which relates scaffold degradation and erosion kinetics under arterial
flow conditions to material parameters that can be controlled in the manufacturing
process, [25, 79, 4, 68, 96, 91, 3]. While our earlier work simulated the evolution and
transport of soluble species both within the scaffold and arterial wall [97], we did not
explore how material parameters impacted by-product fate, and these aspects have
been the focus of the current study.
A two-dimensional computational model of a tissue-embedded PLLA scaffold was
developed to characterize the effects of compositional and structural parameters on
LA accumulation within the arterial wall. Degradation and erosion kinetics were
quantified for 120 days from initial deployment using metrics such as reduction in
scaffold weight-average molecular weight (Mw) and weight (Wt), respectively. Within
the same period, transient LA tissue levels were quantified via a surface integral of
the concentration field in the local arterial wall. Model predictions suggest that
some material parameters have a similar effect on degradation and erosion processes,
while others induce qualitatively opposing responses. Moreover, peak LA levels in
surrounding tissue and the times at which these levels occur exhibit high sensitivity
to scaffold molecular structure and the amount of lactide doping. PLLA composition
and structure can be tuned to control both degradation and erosion processes, and
ultimately mitigate the risk associated with by-product accumulation in endovascular
scaffold applications.
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3.3 Methods
A two-dimensional computational model of a tissue-embedded PLLA scaffold was
developed with geometrical regions representing a single scaffold strut (S) fully em-
bedded within the arterial wall (W), a segment of the arterial wall adjacent to the
strut termed the critical zone (CZ), and the arterial lumen (L) (Figure 3.1A). The
diameter and length of the lumen were 3 × 10−3 m and 1 × 10−2 m, respectively,
the thickness of the arterial wall was 1× 10−3 m, the side-length of the square strut
was 1 × 10−4 m, and width and thickness of the critical zone were 8 × 10−4 m and
4× 10−4 m, respectively. Blood was considered as an incompressible and Newtonian
fluid. Blood flow through the lumen was assumed to be steady, laminar, and fully-
developed, and was modeled using momentum and continuity equations as follows:
ρL (uL · ∇)uL = −∇PL + µL∇2uL (3.1)
∇ · uL = 0 (3.2)
where uL, ρL = 1060 kg m−3, µL = 3.5× 10−3 Pa-s [75], and PL are respectively
luminal blood velocity, density, viscosity, and pressure.
Steady blood plasma flow through the porous arterial wall was modeled using
momentum and continuity equations as follows:
ρW (uW · ∇)uW = −∇PW + ( 1
W
)µW∇2uW − (µW
κW
)uW (3.3)
∇ · uW = 0 (3.4)
where uW, ρW = 1025 kg m−3, µW = 7.2× 10−4 Pa-s, [75, 97] and PW , are respec-
tively transmural blood plasma velocity, density, viscosity, pressure, whereas, κW =
1.43× 10−18 m2 and W = 0.43 [45, 45] are respectively Darcy’s permeability and
porosity of the arterial wall.
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Figure 3.1 (A) Schematic of the two-dimensional computational framework
consisting of a scaffold strut (S) fully-embedded within the arterial wall (W), a
critical zone (Cr) in the arterial wall surrounding the scaffold, and the arterial
lumen (L) (not to scale). Surface plots of LA concentration in the scaffold (B),
critical zone (C), lumen (D), and arterial wall (E) at 30 days post-implantation.
Color bars represent LA concentration for each inset.
In the present study, degradation refers to a chain scission process where poly-
mer chains are cleaved into oligomers and monomers, while erosion reflects material
loss from the bulk polymer due to release of water soluble oligomers and monomers.
Though PLLA can undergo both autocatalytic and un-catalytic reactions [92], only
autocatalytic reaction was considered in this study as the scaffold was fully embedded
in the arterial wall and water-soluble by-products were unlikely to be washed away
immediately from the scaffold but they acted as catalysts that enhance further degra-
dation. Further, the thickness of the scaffold was 0.1 mm, which was well below the
critical thickness for surface erosion (0.2 - 0.3 mm) [28], suggesting that the scaffold
underwent primarily bulk erosion.
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Figure 3.2 (A) Random scission of ester bond with equal probability. (B) Any
constituent can randomly produces a specific daughter constituent in two ways or
two molecules of a specific daughter constituent.
Each ester bond within constituent PLLA chains was assumed to undergo random
scission with equal probability and generate two daughter oligomers of lower molecular
weight [96, 4]. Hence, production of any specific constituents from a longer chain can
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randomly occur in two ways (Figure 3.2). Amorphous regions of the scaffold were
subjected to degradation due to a favorable water penetration condition, while the
crystalline polymer regions were considered stable [85, 30]. Initial and generated
polymer chains with carboxylic acid end groups were assumed to catalyze subsequent
degradation [4]. Moreover, polymeric constituents below the solubility limit (8◦ of
polymerization) were assumed to undergo transient release from the scaffold into
the surrounding medium [71]. Degradation of the longest constituent chain in the
scaffold, Pn, is described by the following rate equation:
dCSn
dt
= −nkCSnA (3.5)
where n,CSn , k, and A are respectively the number of ester bonds, concentration of in
the scaffold, hydrolytic degradation rate, and autocatalysis factor that accounts all
constituents containing carboxylic acid end groups. The hydrolytic degradation rate
was assumed to be equal irrespective of chain length.
dCSi
dt
= −ikCSi A+ 2
n∑
m=i+1
kCSmA; 8 ≤ i < n (3.6)
where CSi is the insoluble constituent concentration; is number of ester bonds, and
CSm is any insoluble constituents concentration with number of ester bonds between
n and i + 1 in the scaffold The concentration and transport of scaffold constituents
below the solubility limit were modeled by diffusion-reaction equations as follows:
∂CSj
∂t
= ∇ · (DSj ∇CS5 )− jkCSj A+ 2
n∑
m=j+1
kCSmA; 0 < j < n (3.7)
where CSj and DSj are respectively the soluble constituent concentration and the diffu-
sion coefficient, j is number of ester bonds, and CSm is any constituents concentration
with number of ester bonds between n and j + 1 in the scaffold.
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Monomer, LA (P0) concentration within the scaffold was described as follows:
∂CS0
∂t
= ∇ · (DS0∇CS0 ) + 2
n∑
m=1
kCSmA; 8 ≤ i < n (3.8)
where CSj and are DSj respectively LA concentration and diffusion coefficient, CSm is
any constituents concentration with number of ester bonds between n and 1 in the
scaffold. Polymer degradation increases the scaffold porosity and the diffusion coeffi-
cients of all mobile chains. Hence, the diffusion coefficients of soluble constituents at
any time, Dt, were calculated as follows [92]:
Dt = D0[1 + αp] (3.9)
where D0, α, and p are respectively the initial diffusion coefficient, a material-specific
proportionality constant, and scaffold porosity. Porosity of the scaffold increases as
degradation takes place and was taken into account in the model through calculating
the concentration of the available species in the scaffold [92].
The degree of polymer crystallinity Xc0 represents the volume fraction of crys-
talline regions throughout the scaffold, and can change in two ways: (a) crystal-
lization of small degradation by-products because of their greater mobility and (b)
accelerated amorphous regions degradation and erosion as compared to the crystalline
regions [30]. The temporal variation in PLLA Xc0 was described by an adaptation of
the Avrami equation that neglects degradation within crystalline domains [92, 6]:
Xc −Xc0 = 1− exp[−(kct)nA ] (3.10)
where Xc0, kc, and nA are respectively the initial degree of crystallinity, the temper-
ature dependent degree of crystallinity change rate related to nucleation and growth
parameters at isothermal conditions, and an Avrami constant that depends on the
nucleation mechanism and crystal growth geometry/mechanism.
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The transport of scaffold-derived soluble constituents in the arterial wall were
modeled by transient diffusion-convection-reaction processes as follows:
∂CWj
∂t
+ uW · ∇CWj = ∇ · (DWj ∇CWj )− jKCWj A1 + 2
7∑
m=j+1
kCWm A1; 0 < j < 8
(3.11)
∂CW0
∂t
+ uW · ∇CW0 = ∇ · (DW0 ∇CW0 ) + 2
7∑
m=1
kCWm A1 −KmCW0 (3.12)
where CWj and DWj are respectively soluble constituents concentration and diffusion
coefficient in the arterial wall; j is number of ester bonds; is any soluble constituents
concentration with number of ester bonds between 7 and j+1; CW0 and DW0 are
respectively LA concentration and diffusion coefficient in the arterial wall; A1 is the
total concentration of constituents with carboxylic acid end groups; and km is the
irreversible first-order reaction rate constant that characterizes metabolism of LA in
the arterial wall.
Lastly, transport of soluble constituents in the lumen were modeled as transient
diffusion-convection-reaction processes as follows:
∂C lj
∂t
+ ul · ∇C lj = ∇ · (Dlj∇C lj)− jKC ljA1 + 2
7∑
m=j+1
kC lmA1; 0 < j < 8 (3.13)
∂C l0
∂t
+ ul · ∇C l0 = ∇ · (Dl0∇C l0) + 2
7∑
m=1
kC lmA1 −KmC l0 (3.14)
where C lj and Dlj are respectively soluble constituents concentration and diffusion
coefficient in the lumen; j is number of ester bonds; C l0 and Dl0 are respectively LA
concentration and diffusion coefficient in the lumen.
A steady, Poiseuille parabolic velocity profile with peak velocity of 0.53 m s−1
was imposed at the luminal inlet and a zero pressure boundary condition was applied
at the luminal outlet to simulate coronary arterial flow [75]. The Kedem-Katchalsky
equation was used at the mural interface to define the transport of blood plasma
from the lumen perivascular wall [41, 19]. For simulating mass transfer, the initial
scaffold molecular weight distribution (MWD) was prescribed to achieve specific Mw
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and polydispersity index (PDI). A zero concentration boundary condition was as-
sumed at the luminal inlet and a convective flux boundary condition was imposed at
the luminal outlet and on the perivascular wall. Continuity of soluble constituents
was assumed at scaffold-arterial wall and mural wall interfaces. The Delaunay tri-
angular scheme was used to perform the mesh generation with maximum intensity
of elements focused around the scaffold and critical zone. A finite-element model
(COMSOL MultiphysicsTM) was used to perform numerical simulations and the it-
erations were continued until the relative error tolerance magnitude reached . The
computational solution was considered mesh-independent when the relative change
in scaffold Mw and LA concentration was less than 0.1% at any simulated time step
between successive mesh iterations. The average computational runtime for each sim-
ulation was around 5 hours using an Intel Xeon CPU (2.80 GHz) processor with 20
GB ram.
Accumulation of scaffold-derived LA may lower the local pH below a critical value
and induce toxicity in the arterial wall [53]. The critical zone maximum LA concentra-
tion (CCrLA,max) and the time at which CCrLA,max occurs (tmax) are therefore considered
as performance metrics for scaffold safety assessment. Degradation and erosion ki-
netics are typically monitored by tracking the Mw and Wt change of the scaffold
over time. Hence, degradation and erosion half-lives (t1/2deg and t1/2ero) as defined by the
time at which the initial Mw and Wt are reduced by 50% respectively, are reported
as reduced metrics of the degradation and erosion processes.
3.4 Results
The developed random scission degradation model was validated by comparison to
published data describing the transient reduction inMw of a PLLA disc maintained in
static, phosphate buffer solution [90]. An initial PLLAMw of 7.6 kDa and PDI of 1.34
were imposed in the model to recreate experimental conditions. A theoretical degra-
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Figure 3.3 (A) Transient molecular weight (Mw) profile comparison between
predicted results and experimentally-published values [90]. Best-fit model
parameters included an initial weight-average MW of 7.6 kDa, initial polydispersity
index of 1.34, hydrolytic degradation rate of 1.17× 10−11 m3mol−1s−1, initial
monomer diffusion coefficient of 1× 10−13 m2s−1, constant value of = 4.5, initial
degree of crystallinity of 0.24, and degree of crystallization change rate of
4.63× 10−8 s−1. (B, C) Scaffold weight-average molecular weight (Mw) and weight
(Wt) decrease nonlinearly with time, with relatively fast degradation and slow
erosion at early times. (D) Transient lactic acid (LA) concentration profiles in
different regions show that the accumulation of scaffold-derived by-product is
orders-of-magnitude higher in the critical zone compared to other regions within the
computational domain.
dation curve that exhibited excellent correlation (R=0.99) with experimental results
was generated by tuning model parameters, yielding a hydrolytic degradation rate of
1.17× 10−11 m3mol−1s−1 and initial monomer diffusion coefficient of 1×10−13 m2s−1
(Figure 3.3A). Several experimentally verified-models quantified PLLA hydrolytic
degradation rate with the same order of magnitude [4, 3] and a monomer diffusion
coefficient between 1 × 10−12 - 1 × 10−14 m2s−1 [66, 91], indicating that both fitted
parameters are within a plausible range. The degree of crystallinity change rate and
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Figure 3.4 (A, B) Maximum critical zone LA concentration (CCrLA,max) and the
time which CCrLA,max occurs (tmax) are independent of the standard deviation (σ) of
scaffold molecular weight distribution (MWD). (C, D) Higher σ results in faster
degradation as indicated by the time required for 50% reduction of the initial
weight-average molecular weight (t1/2deg), but does not alter the erosion kinetics as
indicated by the analogous measure of weight loss (t1/2ero).
Avrami constant were calculated by fitting the Avrami equation against experimental
results with an initial degree of crystallization of 0.24 [90].
Isotropic diffusion of all mobile constituents within the scaffold results in a max-
imal LA concentration at the strut center and a monotonic decrease towards all
boundaries (Figure 3.1B). Within the defined critical zone, by-product clearance is
augmented by luminal and transmural flow, resulting in reduced LA concentrations
in tissue adjacent to the mural interface as compared to other regions. Upon reach-
ing the mural interface, LA is rapidly transported downstream by the luminal blood
flow (Figure 3.1D). Conversely, transmural flow convects LA towards the perivascular
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wall, resulting in higher concentrations beneath the scaffold strut (Figures 3.1B &
E). All larger mobile constituents are transported in the same qualitative manner as
LA but at relatively slower rates.
For the case of monodisperse PLLA, scaffold degradation is initiated upon deploy-
ment as indicated by the immediate decrease inMw (Figure 3.3B). ScaffoldMw change
rate is nearly constant for the first 40 days and then is gradually reduced, resulting
in a more than 50% decrease of Mw within first 40 days followed by less than 25%
additional reduction over the next 80 days. Scaffold erosion exhibits qualitatively-
reversed kinetics, with a slow rate of mass loss at early times (t <30 days) followed
by comparatively rapid mass loss for the remaining time (Figure 3.3C). Transient
concentrations of scaffold-derived LA within different model regions exhibit order-
of-magnitude differences over 120 days (Figure 3.3D). LA concentration is always
highest within the scaffold, followed by critical zone, arterial wall, and lumen. Max-
imum LA concentration in the critical zone is 7.6% greater than in the surrounding
arterial wall, motivating the subsequent focus on this region of tissue for risk assess-
ment associated with by-product accumulation.
While maintaining constant number-average molecular weight (MN), the initial
scaffold MWD was systematically varied by increasing the standard deviation (σ)
of the initial chain length distribution. Both CCrLA,max and tmax are minimally af-
fected by the initial scaffold MWD profiles (Figures 3.4A & B). In comparison to the
monodisperse scaffold (σ = 0), maximal polydispersity within our investigated range
(σ = 6000) results in the same CCrLA,max at essentially the same time post-implantation
(1.5 days later). Conversely, faster PLLA degradation, as indicated by a reduction in
t
1/2
deg, is predicted for scaffolds with greater polymeric dispersion (Figure 3.4C). Ap-
proximately 30% decrease in t1/2deg is observed for polydisperse scaffold with σ = 6000
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Figure 3.5 Comparative evolution of PLLA molecular profiles with varying initial
standard deviations (σ) of the molecular weight distribution. The number of
molecules is normalized with respect to total molecules present in the scaffold at t =
0 and presented in the vertical axis.
in comparison to the monodisperse scaffold. Polydispersity has an insignificant effect
on erosion kinetics, as indicated by almost equal t1/2ero among all PLLA variants (Fig-
ure 3.4D). Transient scaffold profiles reveal that after 30 days the MWD is largely
independent of initial PLLA composition (Figure 3.5). These results suggest that the
transformation of large constituents into shorter insoluble oligomers is a rapid process
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Figure 3.6 Hydrolytic degradation results small chain constituents evolution with
wide range of molecular weight (Mw) at the early days followed by more uniform
Mw-rich small chain constituents. Polydispersity index (PDI) is defined the ratio of
weight-average molecular weight to number-average molecular weight. Higher
polydispersity is observed when standard deviation (σ) of initial scaffold molecular
weight distribution increases.
in comparison to soluble by-product generation and mass loss. As a consequence, the
amount of soluble constituents in the scaffold is insignificant compared to insoluble
constituents at all times, irrespective of the initial MWD. Over the range of consid-
ered PLLA formulations, degradation and erosion processes essentially homogenize
all scaffold PDI by 120 days post-implantation (Figure 3.6).
Higher initial scaffold degree of crystallinity (Xc0) results in a linear decrease in
CCrLA,max and a linear increase in tmax within the investigated range (Figures 3.7A &
B). While both degradation and erosion kinetics are depressed with increasing Xc0,
the comparative responses of t1/2deg and t1/2ero suggest erosion is the more sensitive Pro-
cess (Figure 3.7C & D). While t1/2deg is increased by 53%, t1/2ero is increased by 130%
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Figure 3.7 (A, B) Higher scaffold initial degree of crystallinity (Xc0) decreases the
critical zone maximum LA concentration (CCrLA,max) and delays the time at which
CCrLA,max occurs (tmax). (C, D) Degradation and erosion kinetics are protracted by
increasing (Xc0), as represented by increases in the times at which initial scaffold
weight-average molecular weight (t1/2deg) and weight (t1/2ero) diminish by 50%.
within the investigated range. The degree of crystallinity change rate (kc) dictates
how fast crystalline regions become amorphous. Similar to the effect of increasing
Xc0 higher kccauses a decrease in CCrLA,max (Figure 3.8A) with negligible change in
tmax (Figure 3.8B). Increasing kc slows down both degradation and erosion processes,
with a more pronounced effect on the latter as observed by 109% increase within the
investigated range (Figures 3.8C & D).
Lactide doping is expected to have a profound effect on all scaffold performance
metrics via stimulation of autocatalytic processes. Simulation results predict that in-
clusion of lactide within the scaffold significantly increases CCrLA,max and reduces tmax
(Figures 3.9A & B), and accelerates both degradation and erosion (Figures 3.9C &
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Figure 3.8 (A, B) An increased crystallinity change rate (kc) reduces the critical
zone maximum LA concentration (CCrLA,max) and delays the time at which CCrLA,max
occurs (tmax). (C, D) Trends in t1/2deg and t1/2ero suggest that degradation kinetics are
independent of kc, whereas erosion kinetics are protracted with increasing
Degradation and erosion kinetics are protracted by increasing kc.
B). The effect of lactide inclusion on degradation and erosion is similar, as both t1/2deg
and t1/2ero are reduced by 50% when 5 wt% lactide is added to the initial scaffold.
3.5 Discussion
Performance of PLLA-based fully-resorbable endovascular scaffolds critically depends
on scaffold degradation and erosion kinetics. Modulations in the molecular weight
profile, average molecular weight and microstructure (crystallinity and porosity), as
well as incorporation of additives such as lactic acid (LA) are some of the design
aspects that can be adjusted during the manufacturing stages to control the fate of
in vivo by-product distribution. Deeper understanding of these tunable parameters
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Figure 3.9 (A, B) ncorporation of free lactide increases the critical zone
maximum LA concentration (CCrLA,max) and decreases the time at which CCrLA,max
occurs (tmax). (C, D) Excess lactide and its degradation products enhance
autocatalytic hydrolysis and accelerate both the degradation and erosion as
indicated by reductions in t1/2deg and t1/2ero .
is required to enhance overall scaffold performance, and thereby improve the bio-
compatibility and clinical efficacy of erodible devices. We have used computational
modeling to gain insight into the critical determinants of PLLA scaffold degrada-
tion and erosion, by accounting the effects of autocatalysis, polydispersity, degree of
crystallinity, species-specific transport of scaffold-derived constituents, and porosity
change due to degradation, blood flow, and LA metabolism.
Transient concentrations of scaffold-derived degradation by-products are concur-
rently modulated by the rates of diffusion, convection, generation, and metabolism.
A parametric sensitivity analysis was performed to quantify the relative influence of
structural and compositional factors on scaffold performance (Table 3.1). A relative
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change index (RCI) was calculated to quantify the percent change of defined perfor-
mance indicators when material parameters are varied in isolation from the lowest
to highest considered values. The safety assessment of PLLA modifications is based
on the RCIs of CCrLA,max and tmax, whereas degradation and erosion assessments are
based on t1/2deg and t1/2ero , respectively.
Fine tuning of polydispersity was expected to enable a reduction in the inflam-
matory potential of PLLA scaffolds through protraction of LA generation [90]. A
mixture theory based on a previously proposed model suggested that bulk polymer
erosion was significantly affected by initial polydispersity due to early stage solu-
ble constituents overall enhanced diffusivities [79]. However, our results show that
though initial polydispersity affects scaffold LA production, it has negligible effect on
LA accumulation adjacent to the scaffold and only mildly affects degradation (RCI =
Table 3.1 Sensitivity analyses on PLLA structural and compositional parameters.
Relative change index (RCI) is based on percent increase (+) or decrease (-) of
defined performance metrics due to isolated changes of material parameters. Safety
assessment is based on maximum critical zone lactic acid concentration and the
time at which it occurs. Degradation and erosion assessments are based on the
corresponding half-lives (t1/2deg and t1/2ero) when initial scaffold weight-average
molecular weight and weight are reduced by 50% respectively.
Parameter Range
Relative Change Index (RCI)
Safety Assess-
ment (Concen-
tration)
Safety Assess-
ment (Time)
Degradation
Assessment
Erosion As-
sessment
Initial Scaffold
MWD Stan-
dard Deviation
0 - 6000 - 2 % + 2 % - 29 % +2 %
Initial Scaf-
fold Degree of
Crystallinity
0 - 0.3 - 47 % + 36 % + 53 % + 130 %
Degree of
Crystallinity
Change Rate,
s−1
0 -5.8× 10−8 - 40 % - 4 % + 15 % + 109 %
Initial Lactide
Doping, wt%
0 - 5 + 157 % - 48 % - 51 % - 49 %
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+29%). This finding reinforces the notion that it is difficult to predict how a single
material parameter will impact critical zone LA pharmacokinetics that are modulated
by the relative rates of LA generation, diffusion within the scaffold, release into local
tissue, transport within the arterial wall, and metabolism.
Increase in the degree of crystallinity due to the degradation of the amorphous
regions gradually slows overall degradation and erosion rates, as crystalline regions
are relatively resistant to hydrolytic breakdown [2]. Because the degradation rate at
early times is maximal, t1/2deg exhibits a moderate sensitivity to Xc0 (RCI = +53%)
and a mild response to kc (RCI = +15%). On the other hand, erosion rates are
initially slow and thus are highly sensitive to both Xc0 and kc, as reflected in the
corresponding t1/2ero RCIs. Previous studies have reported that PLLA degradation is
accelerated with increasing Xc0 due to two factors: (i) a decreased density of effective
tie chains between adjacent crystalline blocks and (ii) increased void spaces in the
amorphous regions which ultimately prompt hydrolysis by enhancing water diffusion
[85]. However, the degradation response to Xc0 was reported to vary substantially
with polymer processing methodologies, most notably the employed film annealing
temperature, which may account for the contradiction with our current findings [2].
Scaffold Xc0 can be controlled by modifying the annealing and/or quenching pro-
tocols, whereas kc at a specific temperature can be controlled by adding nucleating
agents during the manufacturing process [51]. Hence, both Xc0 and kc provide po-
tential avenues for selective tuning of scaffold degradation and erosion kinetics.
While lactide doping can potentially be used to tune scaffold degradation and
erosion kinetics, the concomitant increase in tissue LA concentration should also be
considered. Our study suggests that lactide doping should be employed with high
precision in scaffold manufacturing due to the promotion of by-product accumula-
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tion. Although the inclusion of lactide has been previously considered and remains a
promising scaffold design strategy, the risk associated with an elevated tissue response
is significant and should be assessed with in vivo studies [70].
3.6 Study Limitations and Future Works
Although the proposed degradation model is verified using previously reported val-
ues from a static experimental study [90], the predicted degradation kinetics under
physiologic conditions have not been validated with or compared to published data.
While only in vivo studies can validate the predictions of this computational model,
the requisite number of studies that would be needed considering the complexity of
synthesizing scaffolds with precise variations of structural properties precludes inclu-
sion of this validation from the current body of work. However, our computational
study is a valuable contribution to the field as it suggests critical parameters that one
may focus on when performing future animal studies. Moreover, the model could be
extended to three-dimensions to better account for flow-mediated processes, but due
to symmetry of the vessel (and most scaffolds as well) and computational cost, the
study was conducted in two-dimensions. In comparison to our earlier study where all
the degradable species were divided into only five groups to identify the dominating
factors that modulate the fate of scaffold derived by-products clearance [75],here we
have tracked all individual species generated during scaffold degradation to better
understand the consequences of structural variations - this resulted in a substantially
more complex model. With our current resources, coupling three-dimensional geome-
try effects with our detailed degradation model would have dramatically increased the
computational time of the simulations (most likely an exponential increase). Com-
putational costs also limit the examination of very high initial Mw-rich scaffolds that
are typically used in endovascular applications. Modeling the performance of high
Mw-rich scaffolds in three-dimensional environments will be interesting to investigate
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in future.
Although degradation processes are theoretically initiated at the time of implan-
tation, PLLA-based bioresorbable scaffolds have been shown to provide structural
support to vessel walls for prolonged times with minimum risk of restenosis [77].
Specifically, the PLLA-based bioresorbable Everolimus eluting stent results in an
acceptable angiographic in-stent late loss, low stent area obstruction, no late throm-
bosis, and minimal neointimal hyperplasia after 6 months post-implantation [62].
While these factors are certainly related to the mechanical strength of the scaffold
that may impact long-term performance, predicting the degradation-induced change
in scaffold mechanical properties is not within the scope of this study. Moreover,
a fully-embedded scaffold was considered in this simulation from the initial stage
though it has been reported that fully bioresorbable vascular scaffolds are completely
covered by the fibromuscular neointima by 4 weeks after implantation [59]. Finally,
the pulsatility of blood flow was neglected due to the fully-embedded scaffold position
and the minimal effect on constituent transport within the arterial wall. These are
important aspects that need to be considered in developing a model to fully appre-
ciate the efficacy of endovascular therapy using biodegradable scaffolds. Our current
study lays a foundation to address these issues which we in fact plan to explore in
our future studies.
3.7 Conclusion
Advanced design of erodible endovascular scaffolds requires careful assessment of ma-
terial properties that impact implant performance and safety in the arterial envi-
ronment. Our study reveals that potential variations in polymer composition and
structure differentially impact metrics of performance. Specifically, we found that
degradation is minimally affected by changes in either PLLA polydispersity or the
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initial degree of crystallinity, while erosion is sensitive to crystallinity. Additionally,
scaffold degradation, erosion, and by-product accumulation were all responsive to lac-
tide doping. Computational modeling serves as an efficient means to evaluate possible
tuning strategies and enable improved design of erodible scaffolds.
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Chapter 4
THE IMPARTED DEGREE OF RADIAL
EXPANSION MODULATES DRUG ELUTING
BIORESORBABLE VASCULAR SCAFFOLD
PERFORMANCE
1
4.1 Abstract
Drug eluting bioresorbable vascular scaffolds (BRS) have the inherent potential to
enable complete restoration the native vascular environment, an insomuch offer a
distinct advantage over permanent percutaneous endovascular intervention technolo-
gies. To ensure that therapeutic gains are conferred for a sufficient period of time
prior to scaffold resorption, the multitude of factors that dictate key metrics of BRS
performance must be identified, characterized, and optimized. Some deterministic
factors are controlled in the BRS design and manufacturing processes, while others
depend on the specific method and site of implantation. The focus of this is study is
to understand how and to what extent the imparted degree of radial expansion at the
time of implantation modulates BRS performance, a factor which falls into the latter
category. The significant variation in target arterial dimensions among individuals,
1Ferdous, J., Fatematuzzahan, Kolachalama V. B., and Shazly T. To be submitted to Journal
of Controlled Release
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e. g. the coronary artery diameter ranges from about 2-5 mm, as well as the differen-
tial geometries presented in various stages of plaque progression, suggest the need to
expand BRS on an application-specific basis. To gain insight on the potential clinical
implications, we systematically varied the radial expansion of a BRS composed of
poly DL-lactide-glycolide and generated in vitro metrics of degradation, erosion, and
drug release kinetics. Experimental data were used to develop a finite-element based
computational model that predicts the transient concentrations of scaffold derived
soluble species and drug in the arterial wall following various degrees of expansion.
Taken together, our results demonstrate that BRS safety and efficacy will be sig-
nificantly influenced by the degree of radial expansion and provide a foundation for
continued product design and development.
4.2 Introduction
Drug eluting bioresorbable scaffolds (BRS) have the potential to displace metallic
drug-eluting stents (DES) as the technology-of-choice in percutaneous coronary in-
tervention (PCI) based on the inherent ability to mitigate the occurrence of late
thrombosis. The transient resorption of BRS could enable gradual restoration of the
native vascular environment, and thus promote complete vessel healing and recovery
of function. Despite this apparent advantage and over thirty years of research and
development [80], the introduction of BRS into clinical practice has been stifled by
regulatory concerns and a lack of the necessary data to demonstrate superiority over
current technologies. Only two manufactured BRS have received the CE mark of
approval, which allows use in the European Economic Area, while none have been
approved by the United States Federal Drug Administration. Although there are a
few pre-clinical and early-phase clinical trials that cumulatively show therapeutic po-
tential, there have been no randomized clinical trials with DES to demonstrate that
BRS specifically lower risk of late and very late stent thrombosis [60].
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In addition to providing superior efficacy over DES, the clinical introduction of
BRS is predicated on a thorough demonstration of device safety that specifically ad-
dresses the risks inherent to erodible implants. A primary risk factor of BRS is the
occurrence of early fracture, which has historically been a concern in metallic DES
and is magnified in polymer-based endovascular devices. While material selection
and fabrication protocols can be tuned to promote the requisite mechanical strength
for the intended therapeutic duration, it is now evident that BRS strut malapposi-
tion and otherwise inappropriate deployment can enhance early fracture rates [61].
Irrespective of the specific base polymer and manufacturing technique, a given BRS
will be limited by a maximum attainable degree of expansion prior to the onset of
mechanical failure [73]. Thus, it is possible that BRS over-expansion at deployment
could induce a fracture that immediately limits the ability of the device to restore lu-
men patency. Conversely and in a similar fashion to DES, under-expansion increases
the risk of thrombosis due to an alteration of in situ scaffold geometry and concomi-
tant disturbance of arterial blood flow [88].
To select appropriate BRS and balloon sizes for a given application, a priori
measurement of vessel lumen diameter is typically performed with quantitative coro-
nary angiography (QCA). Following this preliminary assessment, a surgeon would
then select from a limited number of available BRS sizes and subsequently impart
the necessary degree of radial expansion at deployment based on patient-specific ge-
ometry. Such measures are likely to ensure against instances of obvious over- and
under-expansion, but will not fully eliminate inter-patient variation in the degree of
expansion.
It is logical to posit that the degree of radial expansion will play a significant role
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in determining BRS performance, as the in-situ microstructure of the constituent
polymeric network will accordingly vary and likely impact the rates of key kinetic
processes for an erodible drug delivery device. To better understand the mechanisms
by which device expansion alters device performance, we systematically varied the
degree of radial expansion of BRS composed of poly DL-lactide-glycolide (PLGA)
and generated in vitro metrics of degradation, erosion, and drug release kinetics.
Experimental data were used to construct a finite-element model that predicts the
transient concentrations of released drug and degradation by-products in the arterial
wall. Our findings suggest that the imparted expansion will significantly alter the
clinical safety and efficacy of BRS, and therefore support the need to carefully account
for and control this parameter in device deployment.
4.3 Materials and Methods
Preparation of resorbable scaffolds
A solution-casting method was applied used to prepare PLGA- based resorbable scaf-
folds [89]. Homogenized polymer solutions of research grade, ester terminated 50:50
PLGA having with an inherent viscosity of 0.82 dL g−1 (LACTEL Absorbable Poly-
mers, Alabama, USA) were achieved created by dissolving predetermined amount of
PLGA pellets in dichloromethane (Fisher Scientific, New Hampshire, USA) followed
by stirring for 24 hours at room temperature. To prepare films, tThe polymer solu-
tion was poured on a glass panel and a casting knife with a tunable clearance was
moved over the solution at fixed speed to spread the solution along the direction of
the movement and attain to yield uniform wet film thickness of 60 µm. To enhance
the evaporation of residual dichloromethane from the wet film, the glass plate was
placed in a fume-hood at ambient conditions for 24 hours followed byand then in a
vacuum oven at 50 ◦C for one week. Dry films thickness was tuned through manip-
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Figure 4.1 Helical bioresorbable scaffolds with different degrees of expansion prior
to (A) and after (B) submersion in PBS for various time periods.
ulating the polymer concentration and wet film thickness, and resulting in 150±15
µm thick dry films were achieved as measured using a digital micrometer.
Dried films were cut into a rectangular strips of 70×2 mm2 and wound onto a
Teflon rod. Wound films were then heated at 50 ◦C for 24 hours to form the helical
scaffolds. Finally, a balloon catheter was used to expand the scaffolds inside three
different sizes of Teflon tubes to simulate different degrees of radial expansion (E-1,
E-2, and E-3) as defined by the ratio of scaffold diameter before and after expansion
(Figure 4.1A). Drug containing scaffolds (3% w/w) were prepared by homogenized
mixing of the polymer solution with an 99.5% pure drug Paclitaxel prior to film
formation (LC Laboratories,MA, USA).
In vitro erosion and degradation
Dried scaffolds were weighted (W0) before immersion into the phosphate buffered
saline (PBS) maintained at 37 ◦C and pH of 7.4. PBS medium was replaced daily to
maintain pH levels, which is critical as PLGA polymer degradation is a pH sensitive
process [2]. At predetermined times, samples were weighted after gently removing
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unabsorbed solution from the scaffold surface (Wwet). After multiple rinses with
deionized water, samples were dried at 37 ◦C for one week and weighted (Wdry).
Scaffolds water absorption and erosion/weight loss kinetics were calculated as follows.
Waterabsorption(%) = Wwet −Wdry
Wdry
× 100% (4.1)
Erosion(%) = W0 −Wdry
W0
× 100% (4.2)
Gel permeation chromatography (GPC, Polymer Laboratories) was used to an-
alyze the weight-average molecular weight (Mw) and polydispersity index (PDI) of
dried scaffolds. A linear Mw profile (R2=0.9999) of polystyrene (Polymer Standards
Service, Massachusetts, USA) was used as standards to calibrate the GPC system.
Samples were dissolved in HPLC-grade anhydrous tetrahydrofuran (THF) (Fisher
Scientific, New Hampshire, USA) at a concentration between 10-15 mg mL−1, which
also provided the solvent for the mobile phase of the GPC (flow rate of 1 mL min−1,
injection volume of 200 µL sample−1). Oven temperature was maintained at 30 ◦C
while the pressure was held 4 at Mpa.
Radial strength study
A uniaxial mechanical testing system (3200 testing system, Bose ElectroForce R©, Min-
nesota, USA) was used to measure the radial strength of dried scaffolds. Samples were
placed between two flat compression test fixtures and subjected to a ramped uniaxial
compressive displacement of 0.5 mm at 0.005 mm sec−1. Sample force and displace-
ment data were continuously recorded at an acquisition rate of 10 points sec−1 using
a system integrated software (Wintest R©, Minnesota, USA).
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In vitro Paclitaxel release study
Individual teflon tubes containing drug-loaded dried scaffolds were completely im-
mersed in separate glass vials containing PBS (pH of 7.4) and 10% (v/v) dimethyl
sulfoxide (DMSO) (Fisher Scientific New Hampshire, USA). DMSO was used to en-
hance paclitaxel solubility in PBS and restrict the Paclitaxel adherence with glass
walls [48]. A perfect sink condition was maintained and all glass vials were kept in
the incubator at 37 ◦C throughout the release study. Intact scaffolds at initial time
points were dissolved in acetone to measure drug dissolution (Fisher Scientific, New
Hampshire, USA). Paclitaxel was quantified by an Agilent Series 1100 HPLC (Agi-
lent Technologies, California, USA) equipped with a 4.6×150 mm LiChrospher RP-18
(particle size: 5 µm). The mobile phase consisted of 60% (v/v) HPLC grade acetoni-
trile (Sigma-Aldrich, Missouri, USA) and 40% (v/v) deionized water with a flow rate
1 mL min−1. The injection volume was 100 µ sec−1 and UV detection was performed
at 227 nm with the column oven temperature at 30 ◦C. Paclitaxel retention time was
approximately 5 min. A linear concentration profile (R2=0.99) of 0.1 âĂŞ 100 µM
paclitaxel was used as a standard for calibration (Figure 4.2A).
Morphological characterization
Exterior surface morphology of the scaffolds was analyzed using a variable pressure
scanning electron microscope (SEM) (Tescan Vega-3 SBU) at accelerating voltage of
20 kV. Prior to image acquisition, segments of dried scaffolds were coated using a Den-
ton Vacuum Desk II Gold Sputter (New Jersey, USA) for 60 sec−1 at approximately
35 mA current and chamber pressure of P < 100 mTorr. Scaffold porosities were cal-
culated from the images using a National Institutes of Health developed open-source
image processing program (ImageJ). Computational
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Figure 4.2 Calibration curve for paclitaxel detection.
Computational model
A two-dimensional finite-element model was developed to investigate the effect of
radial expansion on soluble species and drug pharmacokinetics within the arterial
wall. The computational domain was comprised of a cross-section of an arterial wall
with 1 mm thickness, and a single fully-tissue embedded square-shaped scaffold strut
of dimensions 0.1 × 0.1 mm. Degradation was modeled as a random scission process
of ester bonds between monomers, while bulk erosion was modeled as the release of
soluble species from the strut domain [20]. The concentrations of insoluble species
were modeled by the following reaction equations:
dCSn
dt
= −nkCSnA (4.3)
dCSi
dt
= −ikCSi A+ 2
n∑
m=i+1
kCSmA (4.4)
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where n,CSn , k, and A are respectively the number of ester bonds, concentration of the
largest species, hydrolytic degradation rate, and autocatalytic factor; CSi , i, CSm are
respectively the insoluble species concentration, number of ester bonds, and insoluble
species concentrations with the number of ester bonds between n and i+ 1.
The concentrations of soluble species (small oligomers and monomers) inside the
scaffold (CS0 ) were modeled by the following diffusion-reaction equation:
∂CS0
∂t
= ∇ · (DS0∇CS0 ) + 2
n∑
m=1
kCSmA (4.5)
where DS0 is the diffusion coefficient of soluble species in the scaffold that was mod-
elled as an experimentally-derived empirical function of current scaffold Mw. The
concentrations of soluble species in the arterial wall (CW0 ) were modeled by the fol-
lowing diffusion-reaction equation:
∂CW0
∂t
= ∇ · (DW0 ∇CW0 )−KmCW0 (4.6)
where DW0 and Km = 10−5 m2sec−1 are the diffusion coefficient and metabolism rate
of soluble species in the arterial wall, respectively [88].
Assuming diffusion as the dominant transport mechanism for drug within the
arterial tissue and reversible binding to nonspecific tissue sites [14, 50, 52, 87, 86], the
concentration kinetics of Paclitaxel in the arterial wall was modeled by the following
equations:
∂CWp,f
∂t
= ∇ · (DWp ∇CWp,f )−
dCWp,b
dt
(4.7)
dCWp,b
dt
= KaCWp,f (BM − CWp,b)−KdCWp,f (4.8)
where CWp,f and CWp,b, are respectively the concentrations of free and bound Paclitaxel
in the arterial wall; DWp,f = 5.71×10−10 m2s−1 and BM = 13 mol m−3 are respectively
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the Paclitaxel diffusivity and net tissue-binding capacity; ka = 21.97 mol m−3s−1 and
kd = 2.98798 s−1 are respectively the Paclitaxel association and dissociation rate con-
stants [46].
Based on the molecule retention profiles from the GPC, the initial scaffold molec-
ular weight distribution (MWD) was prescribed to achieve initial Mw = 55.757 kDa
and PDI = 1.24. A zero concentration boundary condition was imposed both at the
intramural interface and perivascular wall. Continuity of soluble species concentra-
tions was assumed at the scaffold-arterial wall interface. For drug transport, zero
initial free and bound Paclitaxel concentrations at the arterial wall were imposed.
Assuming erosion mediated drug release and using experimental drug release profiles,
a scaffold weight dependent concentration boundary condition was imposed for the
free drug at the scaffold-arterial wall interface. For the free drug, a zero concentration
condition was applied at the perivascular wall whereas a zero flux boundary condition
was assumed at the intramural interface due to hydrophobicity of Paclitaxel and high
resistance provided by the intima. For the bound drug, zero flux boundary condition
was assigned at mural interface, scaffold-arterial wall interface, and the perivascular
wall.
All transient simulations were solved using a standard finite-element based soft-
ware package (COMSOL MultiphysicsTM , Comsol, Inc.). A Delaunay triangular
scheme was used to mesh the computational domain with maximum intensity of ele-
ments adjacent to the scaffold strut. Iterative mesh refinement was performed until
the relative error tolerance reached 10−5. The numerical solution was deemed to be
mesh independent when the relative change in average arterial wall soluble species
and Paclitaxel (free and bound) concentrations was less than 1% for successive mesh
refinements.
61
Statistical analysis
Results are presented as the average and standard errors of at least three independent
samples at each time point. Considering incubation time and degree of expansion as
independent variables, statistical analyses were performed using both one-way and
two-way ANOVA followed by Tukey’s post-hoc multi-comparison test. Experimen-
tal differences were considered statistically significant at p < 0.05. The coefficient
of determination (R2) and Pearson product-moment correlation coefficient (r) were
computed to respectively assess the goodness of fit of linear regression and strength
of correlation between the independent variables and performance metrics
4.4 Results
Constant initial drug dose and surface area were maintained for all the scaffolds
irrespective of the degree of expansion, implying a variation in scaffold length (Fig-
ure 4.1A). Glassy and flexible initial scaffolds transformed to whitish and brittle
within one week of degradation and began to lose their structural integrity thereafter
(Figure 4.1B). Not surprisingly, water permeated into the scaffold as soon as it was
placed in the buffer solution, resulting in increased scaffold weight with uptake in-
creasing significantly along with incubation time (p < 0.001) (Figure 4.3A)). Scaffold
absorbed water more than 50% of its weight by the end of 14 days. Water uptake was
also significantly affected by the degree of expansion (p < 0.01), with 2-fold higher
expansion of the scaffolds leading to over 40% higher uptake in the first week.
Water uptake by the scaffold immediately resulted ester bonds scission of polymer
chains and generated smaller oligomers and monomers by the hydrolysis reaction as
observed by decreasingMw profiles (Figure 4.3B). Generation of smaller oligomers and
monomers diverged the species MWD profiles and increased PDI the (Figures 4.3C &
D). Average degradation half-life of the scaffolds (t1/2deg), defined as the time at which
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Figure 4.3 Water uptake (A), Molecular weight (B), GPC molecule retention
profile (C), and polydispersity (D) of variably expanded BRS as a function of
submersion time in PBS. * statistically significant at p < 0.05.
the initial Mw is reduced by 50%, were less than one week. Within first two weeks of
degradation, scaffold lost almost 80% of its initial Mw and generated most diverged
MWD profile. After two weeks, presence of smaller oligomers and their degradation
resulted less Mw change and decreased PDI. Meanwhile, higher degree of expansion
resulted faster overall Mw reduction (p < 0.005). Scaffold Mw reduced 44% more
for E-3 in comparison to E-1 after two weeks. Though the Mw profiles of the lowest
expanded scaffold are significantly lower than rest, similar Mw profiles were observed
after 3 weeks irrespective of the degree of expansion.
The time delay between generation of enough soluble species and their release
from the scaffold resulted the slow erosion process at the initial stage. Hence, almost
no weight loss was observed till two weeks (Figure 4.4A). Scaffolds started to lose
weight gradually after three weeks and by week four, E-1, E-2, and E-3 lost 29%,
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Figure 4.4 Weight loss (A) and paclitaxel release (B) profiles from variably
expanded BRS over 28 days submersion in PBS. * statistically significant at p <
0.05.
36%, and 42% of their initial weight, respectively. The erosion half-life of the scaf-
folds (t1/2ero), defined as the time at which the W0 is reduced by 50%, was predicted
from the erosion kinetics profiles as more than four weeks irrespective of the degree of
expansion. Though degree of radial expansion does not affect the overall erosion ki-
netics (p > 0.1), E-3 lost 38% higher weight than that of E-1 in four weeks (p < 0.05).
Drug slowly released from the scaffolds at the initial stage where less than 10% of
total initial drug was released in first two weeks (Figure 4.4B). However, faster drug
release was observed in next two weeks with almost 50% of initial drug released by four
weeks. No burst release of Paclitaxel was observed for any of the scaffolds. Degree of
radial expansion markedly enhanced Paclitaxel release kinetics (p < 0.001). Scaffolds
having lowest expansion ratio released less amount of drug than other scaffolds. At
the end of four weeks, almost 20% more Paclitaxel was released when scaffold degree
of expansion was increased from E-1 to E-3.
Characterization of scaffold’s mechanical property is very critical to understand-
ing its effectiveness to support and retain native vessel structure and prevent recoil-
ing. Therefore, response in mechanical properties due to degradation and different
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Figure 4.5 Compressive load vs. displacement profiles (A-C) and radial strength
as measured by the compressive modulus (B-D of variably expanded BRS over 7
days submersion in PBS. * statistically significant at p < 0.05.
degrees of expansion are important to investigate. All forces were normalized with
corresponding scaffold length to minimize the effect of contact surface area. Compres-
sive modulus (Ec) represented the radial strength of the scaffold and were calculated
based on the slope of the linear regression model of force exerted by the scaffold for
0 to 0.3 mm displacement (Figure 4.5A. All the scaffolds lost their radial strengths
as degradation took place as indicated by the decreased Ec (Figure 5D) where E-1
lost more than 90% of its initial radial strength by one week. Higher degree of ex-
pansion significantly altered the initial and E-1 exhibited 6-fold higher initial radial
strength than that of E-3 (p < 0.05). Overall, radial strength of E-1 was estimated
to be significantly higher than that of E-3 over the investigated one week (p < 0.01).
Non-uniform scaffold structure limited radial strength investigation after one week.
SEM of the scaffolds surface illustrates that the porosity significantly increased
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Figure 4.6 Porosity of variably expanded BRS over 14 days submersion in PBS. *
statistically significant at p < 0.05.
with the degradation time (p < 0.001) and degree of expansion (p < 0.001) (Fig-
ure 4.6). Although the initial scaffold porosity was negligible, E-3 resulted more than
20-fold and 3-fold higher void areas than that of E-1 after one and two weeks of
degradation, respectively. Almost similar pore size was observed over the degrada-
tion period, hence number of pores homogeneously increased with time and degree of
radial expansion. Computational model-based predictions of the degradation profiles
showed excellent correlation with experimental findings (Figure 4.7), where an initial
soluble species diffusion coefficient of 1 × 10−13 m2s−1 and hydrolytic degradation
rate of 4.0× 10−8 m3mol−1s−1, 4.3× 10−8 m3mol−1s−1, and 4.6× 10−8 m3mol−1s−1
were estimated for E-1, E-2, and E-3, respectively.
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Figure 4.7 Transient MW profiles of scaffold having different degree of radial
expansion comparing the predicted results with experimental findings.
Isotropic diffusion and homogeneous initial distribution of soluble species inside
the scaffold yielded maximal soluble species concentration at the core of the strut
(Figure 4.8A). Meanwhile, clearance from intramural surface due to blood flow re-
sulted minimal species accumulation in the regions adjacent to the intramural surface
and strut. Accumulation of soluble species in the arterial wall at the early stage (until
30 days) demonstrated that the rate of species release from the scaffold exceeded the
clearance within this time span. Degree of expansion markedly influenced the peak
arterial wall soluble species concentration (Figure 4.8B). Peak soluble species con-
centration was increased by 15% when the scaffold was expanded 2-fold more from
E-1 even though only 5% more weight loss was observed at corresponding time points
(Figure 8C). This result leads to the inference that the degree of expansion indirectly
modulates the hydrolytic degradation rate and controls the soluble species release
kinetics from the scaffold accordingly.
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Figure 4.8 Soluble species concentration surface plot consisting a scaffold strut
fully embedded within the arterial wall (A). Color bars represent soluble species
concentration for each domain. Arterial wall soluble species concentration (B) and
scaffold weight loss (C) of variably expanded BRS as a function time.
Scaffold implantation immediately resulted in peak Paclitaxel concentration in
the arterial wall that remained invariant until two weeks and started to decrease
thereafter (Figure 4.1B). Degree of radial expansion minimally affected arterial wall
drug content after two weeks and resulted maximum 6% lower drug content in E-3
than E-1. Most of the drug in the arterial wall was available as a bound form as
illustrated by the high bound-to-free drug ratio (Figure 4.9C). Since it required some
time to transport the free drug from the scaffold surface to the perivascular wall,
washout of free drug through the perivascular wall increased the bound-to-free drug
ratio in the later stage. Higher scaffold expansion minimally affected the bound to
free drug ratio and a maximum of 4% higher ratio was observed in E-3 than E-1.
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Figure 4.9 Paclitaxel concentration surface plots within the arterial wall (A).
Color bar represents paclitaxel concentration. Arterial wall paclitaxel concentration
(B) and bound to free drug ratio (C) of variably expanded BRS as a function time.
4.5 Discussion
Initial slow paclitaxel release from the scaffold is controlled by the diffusion, whereas
erosion mediated paclitaxel release in the later stage. Despite of faster hydration, wa-
ter molecules are unable to transport paclitaxel due to hydrophobicity of paclitaxel.
However, onset of erosion markedly enhances the drug release process. Overall, a
good linear correlation is observed between the fraction of released drug and erosion
(R2 = 0.92) (Figure 4.10A). Radial strength of the scaffold are not only dependent
on the initial scaffold deployment but also linearly dependent on the Mw within the
first week of degradation (Figure 4.1B). Scaffolds preserve structural integrity until
50% of initial Mw is available. Rate of Mw decrease is higher than the rate of water
absorption suggesting that on top of hydrolysis reaction there may be other factors
affect the ester bond scission and among which autocatalysis is the major factor.
Meanwhile, higher water absorption rate over erosion confirms bulk erosion which
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Figure 4.10 Paclitaxel release as function of weight loss (A) and compressive
modulus as function of Mw (B) of variably expanded BRS.
was expected for this scaffold as the thickness of the scaffold was below the critical
thickness for surface erosion [28]. Controlled t1/2deg and t1/2ero can be achieved by tuning
the material during the manufacturing process e.g. type of polymer, initial Mw, ad-
ditive, lactide-to-glycolide ratio, end-group capping, porosity, degree of crystallinity,
and taking consideration of implant site environmental situation as Mw change is
markedly affect by the enzyme activity, temperature, pH, and medium flow condition
[2, 20, 23]. All these factors eventually affect the drug release kinetics and radial
strength.
In vitro metrics of BRS performance are significantly influenced by the degree of
deployment. More pore formation under stretched condition favors water penetration
into the scaffold matrix thus enhanced the hydrolytic degradation. As a consequence,
mechanical stiffness of the scaffold is decreased that increases the likelihood of scaf-
fold fracture and loss of structural integrity. Dilation beyond 3.5 mm of a 3.0 mm
resulted strut fracture as observed by the OPT and early restenosis due to early recoil
by the disrupted scaffold [61]. The fractured strut protruded into the lumen, however
it was not clear whether the adverse outcome had any association with strut fracture.
A metallic stent was used to trap the strut against the vessel wall and restore vessel
scaffolding. The fractured strut could be washed away by the blood distal to the strut
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and result severe ramification. The 4.0 mm BRS from Abbott vascular appeared to
be safe and effective when under-expanded in small vessels (<2.5 mm), with similar
clinical and angiographic outcomes observed when compared with those of the over-
expanded in large vessels (>2.5 mm) [16].
Though, under-expansion condition was not considered in the study, smaller ves-
sel size due to under-expanded scaffolds may be less able to accommodate the same
volume of NH as compare to larger vessel and result increased rate of restenosis.
Previous studies on BRS have suggested a association between the thicker struts and
increased risk of restenosis [88]. Although less drug release is observed for low de-
gree of scaffold deployment due to smaller pore volume, fortunately computational
results suggest that the arterial wall paclitaxel concentration is degree of deployment
independent and highly diffusion controlled. Otherwise, lower drug release may not
be strong enough to trigger the therapeutic effect to minimize NH and restenosis
accordingly. Extensive in vivo experiment will be required to investigate the effect of
scaffold deployment of arterial drug content and restenosis rate.
Fate of degradation by-products (soluble species) are considered another impor-
tant safety factor associated with BRS. Excessive accumulation of these acidic by-
products lowers the local pH and could result necrosis. While in vitro/in vivo tracking
of arterial soluble species adjacent to the scaffold strut at different degree of scaffold
deployment are difficult to determined, computational studies provide a complemen-
tary way to predict the soluble species pharmacokinetics. Results indicate that scaf-
fold with higher expansion are more likely to decrease the pH. Arterial soluble species
pharmacokinetics are erosion controlled, hence can be tuned by manipulating the fac-
tors those affect scaffold erosion kinetics. Although the model parameters were used
for paclitaxel based on the porcine femoral arteries and arterial ultrastructure and
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drug type markedly affect the local drug uptake [37], this preliminary study will guide
the future comprehensive in vivo study.
4.6 Conclusion
Personalized medical therapy is an emerging practice of medical treatment offering
tailored solutions to each individual. Although changes in strut design and alternation
of polymeric processing increase the vessel diameter working range, it is suggested to
use site-specific BRS for safe and effective clinical outcomes. Careful and adequate
sizing of vessel diameter are of paramount importance for the correct performance
of this scaffolding technique and require accurate assessment of vessel dimension by
QCA prior to implantation.
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Chapter 5
EFFECT OF DYNAMIC ENVIRONMENT ON
BIORESORBABLE SCAFFOLD PERFORMANCE
1
5.1 Introduction
Late-in-stent restenosis, the primary drawback of current metal based drug-eluting
stent (DES), motivated the innovation of bioresorbable scaffolds (BRS) as an alter-
native to DES that resorb after controlled period of time and restore normal vascular
function [60]. Though first BRS was implanted in human more than 15 years ago
[80], only two types of BRS (Absorb everolimus-eluting bioresorbable vascular scaffold
(BVS) and DESolve R© Novolimus Eluting Coronary Scaffold) met European regula-
tory requirements. There are several procedural, lesion, patient, and design related
factors associated with BRS implantation that can result major post complication.
To determine the robustness of this mode of treatment and compete with current
DES, BRS has to be effective in patients with acute coronary syndromes who have
the highest risk of late and very late stent thrombosis.
Aliphatic polyesters such as poly-lactic acid (PLA), poly-glycolic acid (PGA), and
their copolymers poly-lactic-co-glycolic (PLGA) are most commonly used as biore-
sorbable polymers [57]. Generally, the hydrolytic degradation of these polyester in
1Ferdous, J., Fatematuzzahan, Kolachalama V. B., and Shazly T. To be submitted to Journal
of Controlled Release
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aqueous media proceeds through random ester bond scission between the monomers.
However, degradation causes a increase of the number if carboxylic chain ends which
know to autocatalyze the ester hydrolysis process [25]. Only the soluble species (small
oligomers and monomers) near the exterior surface can escape from the polymer ma-
trix whereas those which are located well inside the matrix remain entrapped ad con-
tribute totally to the autocatalytic effect. Degradation rate also markedly depends o
the amount of water absorption. Release of soluble species depends on surrounding
environments and more specifically factors like solubility, pH, ionic strength, and tem-
perature [2, 23]. These surrounding medium are dynamic of physiological conditions
and nature of the flow in terms of volume, pulsatility, pressure varies among different
arteries. Even the nature of blood flow profiles significantly varies among individuals
along with their sex, and age [17, 72].
Luminal blood flow profiles also modulate the thrombosis formation adjacent to
the strut [69]. Generation of stagnant or recirculation zone around the struts favors
thrombus accumulation. Luminal blood flow profiles also dictate the arterial wall
drug accumulation kinetics [45, 8]. The released drug from the drug-eluting stent
(DES) is entrapped in the stagnant zones that act as a pocket for drug. These ac-
cumulated drug acts as a secondary source and increase the local arterial wall drug
concentration that eventually leads to neointimal hyperplasia.
To reduce the cost and time of clinical trials and animal studies, the effectiveness
of BRS can be preliminary investigated by simple in silico and/or bench top in vitro
experiments that mimic the physiological and pathological environments. In current
study, a in vitro dynamic flow system that mimic the physiological conditions were
developed and compare with static flow system to better understand the effect of
flow. Results indicated that presence of fluid flow significantly altered the scaffold
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performance matrixes as monitored by water uptake, degradation, erosion and radial
strengths duo to autocatalysis. This study motivates to investigate the effect of
pulsatile flow o scaffold performance matrix in future.
5.2 Materials and Methods
Preparation of resorbable scaffolds
Resorbable scaffolds were prepared using PLGA based polymer films and solution-
casting method was applied to prepare the films [89]. Homogenized solutions of
research grade, ester terminated 50:50 PLGA having an inherent viscosity of 1.15 dL
g−1 (LACTEL Absorbable Polymers, Alabama, USA), antiproliferative drug pacli-
taxel (LC Laboratories, Massachusetts, USA), and plasticizer Poly(ethylene glycol)
having averageMw of 4000 kDa were achieved by dissolving them in dichloromethane
(Fisher Scientific New Hampshire, USA) followed by stirring for 24 hour at room
temperature. The polymer solution was then poured on a glass panel and a casting
knife with a tunable clearance was moved at fixed speed to spread the solution to
attain uniform wet film thickness. To enhance the evaporation of residual acetone
from the wet film, the glass plate was placed in a fume-hood at ambient condition
for 24 hour followed by in a vacuum oven at 37 ◦C for one week. The thickness of
the dry films was tuned through manipulating the polymer concentration and wet
film thickness. The thickness of the dried films was 150±15 µm which was measured
using a digital micrometer. The dried films were cut into a rectangular strip of 70×2
mm2 and wound onto a Teflon rod followed by heat at 37 ◦C for 24 hours to form a
helical scaffold. Finally, each scaffold was inserted into a Teflon tube.
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In vitro erosion and degradation
Dried scaffolds were weighted (W0) before immersion into the medium containing
90%(v/v) phosphate buffer saline (PBS) having pH of 7.4 at 25 ◦C and 10% (v/v)
dimethyl sulfoxide (DMSO) (Fisher Scientific New Hampshire, USA). DMSO was
used to enhance paclitaxel solubility in PBS and restrict the paclitaxel adherence
with surface. Since PLGA polymer erosion and degradation are pH sensitive [2], bulk
medium was maintained and medium was replenished with fresh PBS solution in ev-
ery 3-4 days. To simulate static condition, scaffolds were placed into a glass jar with
50 mL of medium at 37 ◦C and ensured that there was no bubble inside the Teflon
rod, hence the scaffolds were completely exposed to the medium. To simulate the
physiologic dynamic condition, a 12-channel peristaltic pump (Ismatec, Germany)
was used and ran at medium velocity of 30 mL min−1(Figure 5.1 & Figure 5.2) [33].
Continuous medium flow was maintained through a closed flow system and 37 ◦C
medium temperature was maintained using a water heater bath. Tube length were
remained constant from the outlet of the pump to the inlet of the test section to
ensure same pressure at the test section.
At every predetermined time intervals, samples were taken out and weighted af-
ter removing the absorbed solution on the surface of the scaffolds (Wwet ). Water
absorption kinetics of the scaffolds was calculated as follows:
Waterabsorption(%) = Wwet −Wdry
Wdry
(5.1)
After multiple rinse with deionized water to wash-out surface PBS , the samples were
dried at 37ÂřC for one week and weighted (Wdry ). Erosion or weight loss kinetics of
the scaffolds was calculated as follows:
Erosion(%) = W0 −Wdry
W0
(5.2)
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Figure 5.1 Experimental of the simulated dynamic system containing the
peristaltic pump, test section with scaffold, PBS reservoir in water bath at 37 ◦C.
Gel permeation chromatography (GPC) from Polymer Laboratories was used to
analyze the weight-average molecular weight (Mw) and polydispersity index (PDI) of
dried scaffolds. A linear Mw profile (R2=0.9999) of polystyrene (Polymer Standards
Service, Massachusetts, USA) was used as standards to calibrate the GPC system.
HPLC grade anhydrous tetrahydrofuran (THF) (Fisher Scientific, New Hampshire,
USA) was used to dissolve the polymer at a concentration between 10-15 mg mL−1
and as a solvent for the mobile phase of the GPC at a flow rate of 1 mL min−1. For
each sample, 200 µL of the dissolved solution was injected into the GPC. Temperature
of the oven was maintained at 30 ◦C while the pressure was approximately 4 MPa.
Radial strength study
Radial strength of the dried scaffolds was measured using an ElectroForce R© load frame
3200 testing system from Bose R© (Minnesota, USA). Samples were placed between two
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Figure 5.2 Schematic diagram of the simulated dynamic system containing the
peristaltic pump, test section with scaffold, PBS reservoir in water bath at 37 ◦C.
flat compression test fixtures and were subjected to a ramped uniaxial compressive
displacement of 0.5 mm at a rate of 0.005 mm sec−1. Sample forces and displacements
data were continuously recorded at a data acquisition rate of 10 points sec−1 using a
software package Wintest R© Software (Minnesota, USA).
Statistical analysis
Results are presented as the average and standard errors of atleast three independent
samples at every time points. Considering incubation time and medium flow condition
as independent variables, statistical analyses were performed using two-way ANOVA
followed by Tukey’s post-hoc multi-comparison test. Experimental differences were
considered statistically significant at p < 0.05.
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Figure 5.3 Helical bioresorbable scaffolds before and after submersion in PBS for
various time periods under static and dynamic conditions.
5.3 Results
The helical shape of the BRS at static flow was lost after 7 days of submersion in
PBS, whereas it retained the initial shape even after 28 days of submersion in PBS
at dynamic condition (Figure 5.3). Length of the scaffolds increased as they degraded.
Water uptake by the scaffolds are significantly affected by the nature of flow
medium (p < 0.001) (Figure 5.4). Rate of water absorption increased abruptly after
one weeks of submersion in static condition and continued till third weeks. Mean-
while, amount of water uptake in dynamic conditions very slowly increased over the
4 weeks of experiments. At the end of 4 weeks almost 1800 folds more water was
absorbed in static condition than that of dynamic condition.
Hydrolytic degradation as result of random ester bonds scission between monomers
took place immediately after submersion of BRS into the PBS irrespective to the flow
condition (Figure 5.5). Since water absorption triggers degradation, BRS in static
condition degrades significantly faster than that of the dynamic condition (p < 0.001).
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Figure 5.4 Water absorption by BRS under static and dynamic flow conditions
after submersion in PBS at various time points.
BRS in static flow condition lost more than 60% of its initial Mw in 1 week, whereas
more than 50% of initial Mw is still available after 4 weeks of submersion in PBS.
Dynamic flow preserved more than 90% BRS Mw than static flow after 28 days of
degradation. Distribution of oligomers and monomers inside the BRS were also in-
fluenced by the nature of flow. Generation of smaller oligomers due to degradation
increased the PDI in the early stage, however after certain period of time (4 days
and 2 weeks for static and dynamic conditions respectively) bigger molecules start
to diminish that lowered the PDI. At the end of 28 days, oligomers having almost
similar Mw were available in BRS under static flow condition as observed by the near
unity PDI.
Erosion, as measured by the weight loss due to release of water soluble oligomers
and monomers from the polymer matrix, was also significantly high for the BRS
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Figure 5.5 Normalized molecular weight (A) and polydispersity index (B) of BRS
polymer matrix under static and dynamic flow conditions after submersion in PBS
at various time points.
under static flow than the dynamic flow (p < 0.01) (Figure 5.6). Negligible weight
loss was observed upto 1 week irrespective to the flow condition. After 1 week, BRS
started to loose weight exponentially under static condition, whereas linearly and
slowly loose under dynamic condition. After 28 of immersion, BRS lost 85% more
of its weight under static condition than that of dynamic condition. Higher rate of
water absorption than weight loss the bulk erosion of the BRS.
Characterization of scaffold mechanical property is very critical to understand
its effectiveness to support and retain native vessel structure and prevent recoiling.
Therefore, response in mechanical properties due to degradation and flow are impor-
tant to investigate. All forces were normalized with corresponding scaffold length
to minimize the effect of contact surface area. The toe regions, as defined by the
distance required for 0 to 0.001 N mm−1 compressive load (Figure 5.7), exhibited by
the BRS were not significantly affected by the flow after degradation for 1 week (p >
0.05). Compressive modulus (Ec) represented the radial strength of the scaffold and
were calculated based on the slope of the linear regression model of force exerted by
the scaffold after the toe region.
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Figure 5.6 BRS weight loss under static and dynamic flow conditions after
submersion in PBS at various time points.
Radial strength after 1 week degradation were significantly increased (more than
100%) when the BRS were exposed to flow (p < 0.005). BRS from the dynamic
condition exerted force linearly until the maximum allowed force of the load cell. On
the other hand, both elastic and plastic regions were observed when BRS from the
static condition were subjected to compressive displacement. The average yield and
ultimate strengths were approximately 0.05 N mm−1 and 0.055 N mm−1 respectively.
Though BRS from static flow condition exhibited necking at high displacements, no
breaking point (fracture) was observed with the investigated 1 mm displacement.
5.4 Discussion
Inclusion of PEG markedly increased the water absoption that eventually enhanced
the degradation and erosion processes significantly. PEG could restricts the release of
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Figure 5.7 Force exerted by a representative BRS due to compression (A) and
effect of flow on BRS compressive modulus and toe region (B) under static and
dynamic flow conditions after submersion in PBS for one week.
soluble oligomers and monomers by obstructing the small pores in the early stage and
thus increases the autocatalysis effect that explains the early fast degradation and
slow erosion processes [36]. However, along with the increase in porosity, the effect
of autocatalysis diminishes as the soluble species could easily released out into the
bulk medium. PEG also increased the flexibility of the BRS under low displacement
as observed by the toe region which is important as BRS is always under pulsetile
flow in in vivo condition. Due to the toe region, the BRS can easily deform with the
artery to accommodate the flow change without extra stress that could be harmful
to the artery. Too much PEG could also make very flexible BRS which enhance the
likelihood recoiling. Therefore, it is important to tune the PEG content by consider-
ing its effect degradation, erosion, and mechanical properties.
BRS in vitro performance matrices are significantly influenced by the nature of
the flow of the medium. Dynamic flow condition markedly decreases the water ab-
sorption, degradation, erosion and radial strength. In the static flow condition, water
can easily diffused into the scaffold (Figure 5.8A). Homogeneous water uptake as con-
firmed by the absent of no swelling fronts results uniform hydrolytic polymer chain
scission all over the scaffold. As a result, the generated carboxylic acid groups lowers
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Figure 5.8 BRS polymer degradation/erosion mechanism under static (A) and
dynamic (B) flow conditions.
the pH value inside the polymer scaffold and accelerates the degradation kinetics in-
side the polymer bulk [28]. As uniform neutral pH is maintained at the surface of the
scaffold, a pH gradient is developed that slow down the degradation of the scaffold
surface compared to the center. Scaffold mass loss occurs due to the release of soluble
monomers and oligomers when the scaffolds forms a network of pores after certain
critical degree of degradation[42].
In the dynamic flow condition, water diffusion inside the scaffold was decreased
because of the flow direction, which delayed the hydrolytic cleavage of eater bonds
inside the polymer matrix (Figure 5.8B). The cleavage of ester bonds occurred pre-
dominantly at the surface of the polymer because of probability of the water contact
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with polymer surface increased due to the medium flowing. However, this is not sur-
face erosion as for surface erosion mass loss starts at the beginning of the experiment
while Mw does not change in early stage [26]. In contrast, Mw started to loose from
the beginning whereas no significant mass loss was observed till 2 weeks in current
study. Mass loss in dynamic condition can be described as delayed bulk erosion.
Generated carboxylic acid groups did not accumulate and washed out by flowing
medium resulting constant pH inside the polymer matrix and cannot contribute in
the hydrolytic degradation process, hence lowered the degradation process and ero-
sion process accordingly.
Since mechanical properties of the polymeric scaffold are dependent on the Mw,
degradation in dynamic condition preserves initial radial strength long than that of
in static condition. Therefore, early fracture is likely in BRS when they are exposed
to static condition. Performing future experiments at several intermediate flow rates
followed under physiologic pulsetile flow would be interesting to investigate.
5.5 Conclusion
BRS in vitro performance matrixes are significantly affected by the nature of the
medium flow. It is important to mention that to investigate any behavior of any
polymeric BRS for endovascular applications, the BRS should be testes in dynamic
condition as the behaviors in the simple static condition do not provide the big
picture. This study will also assist to design implantation site-specific BRS as each
artery are exposed to different flow condition.
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Chapter 6
CONCLUSION
6.1 Overall Conclusion
Tissue remodeling and polymer degradation kinetics modulate lactic acid (LA) ac-
cumulation within adjacent arterial tissue in the case of a tissue-embedded, fully
bioresorbable vascular scaffold (BVS) comprised of PLLA. On the other hand, peak
LA concentrations were insensitive to large variation in the tissue metabolic rate, sug-
gesting that metabolism is a secondary by-product clearance mechanism compared
to diffusive and convective transport. Synchrony between rates of remodeling and
degradation is predicted to minimize peak LA levels in local tissue over the scaffold
lifetime. As BVS are increasingly considered for the treatment of coronary artery
disease, insights on the production and tissue retention of degradation by-products
can help predict clinical performance and provide a basis for iterative device design.
Advanced design of erodible endovascular scaffolds requires careful assessment of
material properties that impact implant performance and safety in the arterial en-
vironment. Potential variations in polymer composition and structure differentially
impact metrics of performance. Specifically, degradation is minimally affected by
changes in either PLLA polydispersity or the initial degree of crystallinity, while
erosion is sensitive to crystallinity. Additionally, scaffold degradation, erosion, and
by-product accumulation were all responsive to lactide doping.
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Personalized medical therapy is an emerging practice of medical treatment of-
fering tailored solutions to each individual. Although changes in strut design and
alternation of polymeric processing increase the vessel diameter working range, it is
suggested to use size-specific BRSs for safe and effective clinical outcomes. Careful
and adequate sizing of vessel diameter are of paramount importance for the correct
performance of this scaffolding technique and require accurate assessment of vessel
dimension by QCA prior to implantation. BRS in vitro performance matrixes are also
significantly affected by the nature of the medium flow. It is important to mention
that to investigate any behavior of any polymeric BRS for endovascular applications,
the BRS should be testes in dynamic condition as the behaviors in the simple static
condition do not provide the big picture. This study provides important insights to
guide the future safe and effective use of vascular polymeric BRS in a patient specific
manner.
6.2 Future Studies
1. Effect of luminal blood flow rates on BRS performance: Based on the out-
comes of dynamic flow effect on BRS performance, it will be interesting to
investigate how different flow rates within the physiological will affect the BRS
performance.
2. Effect of blood flow pulsatility on BRS performance: Blood flow pulsatility
markedly altered the blood flow profiles adjacent to the strut, wall shear stress,
and arterial wall drug accumulation [60]. Therefore, it will be also interesting
to investigate the effect of blood flow pulsatility on BRS performance.
3. Effect of coronary artery curvature on BRS performance: Curvature of coro-
nary arteries is different among individuals and even one single coronary artery
dynamically changes in morphology through the heart cycle. Acute changes
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in the geometry of coronary arteries after implantation of BVS can affect the
clinical outcomes. The most important device property that determines these
changes in vessel geometry is the conformability as described as the flexibility
of a device in its expanded state with adaptation to the natural shape of the
vessel, hence minimizing trauma to the vessel wall [13]. Flow profiles and stress
distribution in the vessel wall are also affected by the curvature of the arteries
[93]. Though current clinical trial indicates better conformability of BRS than
convention metallic stent, further investigations will be required for to confirm
this differences [24]. An in vitro model having controlled variation in vessel
curvatures can be prepared to investigate the transient characteristics of the
BRS which will assist to design in vivo experiments prior to expensive clinical
studies.
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